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Epigenetics of Cardiac Wound Healing 
 
Abstract 
Remodeling of cardiac tissue architecture is essential for normal organ development and 
maintaining homeostasis after injury.  Injurious insults to the heart, such as hypertension and 
myocardial infarction, promote cellular responses including stimulation of resident inflammatory 
cells, activation of endothelial cells and recruitment of immune cells, hypertrophy of 
cardiomyocytes and activation of fibroblasts.  The physiological goal of this coordinated cellular 
response is to repair damaged tissue whilst maintaining or restoring cardiac contractile function.  
Persistent uncontrolled inflammation, hypertrophy and fibrosis in the heart due to hyperactive 
wound healing are detrimental and impair cardiac performance, facilitating the progression to 
heart failure.  Abnormal changes in gene expression promote acquisition of aberrant cellular 
phenotypes that drive cardiac remodeling.  DNA methylation and histone modifications are 
epigenetic mechanisms that critically regulate chromatin structure and gene expression, and are 
essential for normal physiology and development.  Increasing clinical and experimental evidence 
suggests that these epigenetic mechanisms are involved in driving aberrant wound healing and 
the development of heart failure.  While most of our knowledge to date is on the heart as a whole, 
the precise contribution of DNA methylation and histone modifications in regulating aberrant 
cardiac remodeling at the cellular level is less defined.  Therefore, this overview aims to 
summarize the role of DNA methylation and histone modifications (acetylation and methylation) in 
heart failure and to comprehensively dissect the role these mechanisms play in regulating the 
function of cardiomyocytes, fibroblasts and immune cells in response to injury. 
 
Didactic Synopsis 
Cardiac remodeling is a crucial feature of myocardial responses to injury.  Epigenetic alterations 
and regulation of this multifactorial process are at the forefront of cardiac remodeling research, 
including the delineating of cell-type specific contributions. This comprehensive review will 
support undergraduate and postgraduate teaching of concepts relating to the role of epigenetics 
in dictating inflammatory, fibrotic, and hypertrophic responses in the context of cardiac injury. 
Major Teaching Points: 
1) Understanding wound healing responses of both resident cardiac cells and infiltrating 
inflammatory cells, in pathological settings such as myocardial infarction and pressure 
overload, is necessary to appreciate the complex pathophysiology that leads to the 
development of heart failure. 
2) Epigenetic mechanisms such as DNA methylation and post-translational modifications 
(acetylation and methylation) of histone tails are important regulators of gene expression and 
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are now considered to be involved in promoting abnormal cardiac wound healing through, 
extracellular matrix deposition, myocyte hypertrophy and inflammatory mediator release.  
3) Epigenetic mechanisms critically regulate cellular phenotype and function; 
a) Alterations in DNA methylation (e.g. DNMT3 enzymes) and histone modifications (e.g. 
HDAC2) can influence the hypertrophic response in post-mitotic cardiomyocytes. 
b) Increased DNA methylation in cardiac fibroblasts is associated with sustained activation 
and extracellular matrix deposition. 
c) Immune cell phenotype, cytokine release and immune response (trained immunity vs 
immunotolerance) are regulated by both DNA methylation and histone modifications. 
4) Advancements in therapeutic targeting or manipulation of the epigenetic machinery in cells 
implicated in aberrant cardiac remodeling may yield novel treatment strategies in the future 
management of cardiac diseases including heart failure. 
 
Introduction 
Heart failure is a complex disorder that is one of the leading global causes of morbidity and 
mortality, and is associated with a significant economic cost (129, 231).  It is the most common 
cause of hospitalization in patients aged 65 years and over (183) and while therapeutic advances 
have been encouraging (231), the outlook for patients with heart failure still remains a concern as 
roughly half of all patients die within 5 years of diagnosis (107). 
The progression to cardiac failure begins with pathological insults to the heart.  These insults can 
be acute, as in the case of an ischemic injury due to myocardial infarction or chronic damage 
inflicted as a result of hypertension (HTN), metabolic dysfunction (diabetes and obesity), 
inflammatory disease (myocarditis), toxins (alcohol, cytotoxic drugs), genetic mutations, valvular 
disease and prolonged arrhythmias (66, 166, 319).  Regardless of the origin, injury to the heart 
evokes a diverse and complex array of cellular responses involving cardiomyocytes and non-
muscle cells, including fibroblasts, endothelial cells and immune cells in order to repair damaged 
tissue and remodel the myocardium in order to maintain cardiac function (37, 42, 176).  Persistent 
injury or exaggerated wound healing responses can lead to aberrant cardiac tissue remodeling 
that impacts on cardiac function.  This remodeling of the heart, which manifests clinically as 
changes in the size, shape and function of the heart, is now accepted as a key determinant of the 
clinical course of heart failure (66).  Whilst different types of injury activate overlapping cellular 
responses, the pathophysiological consequences can be quite different.  For example, myocardial 
infarction induces myocyte death in the ischemic region that is accompanied by inflammation and 
reactive fibrosis (scar formation).  Reduced cardiac contractility leads to systolic dysfunction and 
heart failure with reduced ejection fraction.  On the other hand, chronic hypertension (increased 
cardiac afterload) leads to inflammation, interstitial fibrosis and myocyte hypertrophy, ultimately 
leading to reduced cardiac compliance, diastolic dysfunction and heart failure with preserved 
ejection fraction.  Understanding what regulates cardiac cell adaptation to injury requires careful 
consideration of the nature of the injurious insult, the tissue microenvironment, and the cell types 
involved. 
Whilst much work has focused on understanding the role of specific transcription factors in 
regulating transcription from response elements in the promoters of specific disease-modifying 
genes, it is now known that epigenetic control of chromatin structure and transcriptional 
machinery plays a crucial role in shaping both individual and global gene expression patterns and 
regulating sustained changes in cellular phenotypes.  Epigenetics is the heritable modulation of 
gene activity that is independent of the underlying DNA sequence.  Epigenetic modifications 
include DNA methylation, histone modifications (e.g. acetylation and methylation) and non-coding 
RNAs (e.g. micro RNAs and long non-coding RNAs) (138, 149).  Epigenetic modifications are 
fundamental for early development along with participating in various biological processes such 
as cellular proliferation and sustaining cellular identity (26, 221).  Alterations to these epigenetic 
regulatory mechanisms have been implicated in numerous disease pathologies including 
imprinting disorders, cancer, neurodegenerative disease and cardiovascular disease (84, 232, 
  3 
261).  Therefore, it is no surprise that epigenetic alterations in response to acute or chronic injury 
may participate in driving aberrant cardiac wound healing. 
A major issue with our understanding of epigenetic alterations in cardiac disease is that changes 
have largely been assessed in whole heart tissue, which contains a mixed cell population of 
cardiomyocytes, fibroblasts, endothelial cells, progenitor cells and immune cells.  This makes it 
very difficult to distinguish which cells these pathologically-driven epigenetic changes are 
occurring in.  Given the emerging evidence that epigenetic therapy has a beneficial impact in 
animal models of heart failure it is becoming increasingly important that we understand the 
mechanisms by which such therapies modulate cardiac cell function and the cardiac response to 
injury.  This overview will focus on the impact of the epigenetic modifications, DNA methylation 
and histone modifications (acetylation and methylation), in the cellular effectors of cardiac 
remodeling and aberrant wound healing, focusing specifically on cardiomyocytes, fibroblasts and 
immune cells (Figure 1).  For a full list of abbreviations please see Table 1. 
 
Aberrant Cardiac Wound Healing and Heart Failure 
The use of various animal models of heart failure and human clinical samples has allowed us to 
dissect out the pathophysiological events that drive cardiac wound healing and tissue remodeling 
subsequent to cardiac injury.  The initial insult to the heart, results in cellular death, tissue 
hypoxia, local cytokine production and generation of reactive oxygen species (ROS).  These 
drivers promote immune cell infiltration to resolve tissue damage and to initiate wound healing in 
the heart.  Cells of both the innate and adaptive immune response are implicated, including 
neutrophils, macrophages, monocytes, dendritic cells, B and T cells (86, 100, 301).  These 
infiltrating immune cells release inflammatory mediators (tumor necrosis factor (TNF)-alpha, 
interleukin (IL) 1, IL-8, IL-6, IL-18, macrophage inflammatory protein (MIP)-1α, monocyte 
chemoattractant protein-1 (MCP-1), interferon (IFN)-γ, and transforming growth factor (TGF)-β) 
(36, 40, 95, 118, 327, 370).  Both inflammatory mediators and neurohormonal signals 
(catecholamines, the renin-angiotensin-aldosterone system (RAAS) and endothelin) that are 
circulating and released locally by  resident and infiltrating cells in combination with increasing 
tissue hypoxia and ROS generation have numerous effects that potentiate cardiac remodeling.  
These include promoting fibroblast proliferation and transdifferentiation to myofibroblasts, 
increased production and secretion of extracellular matrix (ECM) components (collagens I, 
collagen III, and fibronectin), endothelial dysfunction, hypertrophy of cardiomyocytes, further 
oxidative damage and cellular death (necrosis or apoptosis) (14, 307, 317).  The long term effects 
of chronic inflammation and persistent aberrant remodeling within the heart are detrimental to 
cardiac function.  In the setting of acute injury, such as myocardial infarction, exaggerated 
inflammation causes a weakening of scar tissue contributing to ventricular dilatation and systolic 
heart failure.  In the setting of pressure overload chronic inflammation drives exaggerated wound 
healing responses and interstitial fibrosis that contributes to decreased compliance and diastolic 
dysfunction.  As 75% of heart failure patients have antecedent hypertension (231) it is likely that 
many that suffer myocardial infarction already have evidence of pressure-overload related 
interstitial fibrosis and ventricular hypertrophy. 
Cardiac hypertrophy involves the enlargement of myocytes in order to reduce ventricular and 
septal wall stress and maintain stroke volume by increasing contractile capacity (165).  The 
hypertrophic response can be induced in physiological situations, such as exercise and 
pregnancy.  However in these situations the hypertrophy of myocytes is finely tuned and mirrored 
with a consistent supporting vascular network with no evidence of accompanying cardiac fibrosis 
(190, 247).These features are not observed in the pathological setting; sustained myocyte 
hypertrophy becomes maladaptive and is positively associated with the development of heart 
failure.  These defective changes in the cardiomyocyte include alterations in energy metabolism, 
cytoskeletal structure, myofilament function along with abnormal calcium regulation and 
excitation-contraction coupling (140, 174, 187, 319). 
In many pathological settings cardiomyocyte hypertrophy is accompanied by increased ECM 
deposition, presumably with the goal of providing a more rigid scaffold to cardiac myocytes.  
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Production and enzymatic degradation of ECM is a finely controlled process, through matrix 
metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs), and is essential 
for maintaining normal tissue architecture, especially after tissue injury.  The molecular 
composition of the cardiac ECM and the cells and enzymes that are involved in ECM turnover 
have been comprehensively reviewed elsewhere (196, 320).  Myofibroblasts are a principal 
cellular element involved in cardiac wound healing.  At the site of injury, these mesenchymal cells 
(that express α-smooth muscle actin, αSMA) become activated, produce and secrete ECM 
proteins and have the ability to contract in order to facilitate wound healing (134, 285, 295).  
In early wound healing responses, degradation of ECM components by inflammatory cell-derived 
MMPs liberates bioactive fragments known as matrikines that promote the inflammatory and 
reparative cascades.  The formation of a provisional matrix derived from extravasated plasma 
proteins facilitates entry of inflammatory cells that promote clearance of necrotic tissue and the 
migration of fibroblasts that transdifferentiate into myofibroblasts.  Early deposition of provisional 
matrix proteins, such as fibronectin, by fibroblasts is followed by the deposition of structural 
collagens by activated myofibroblasts (reviewed in (98)).  During the maturation phase of wound 
healing disorganized thin elastic collagen III fibers gradually become replaced with organized 
thicker collagen I fibers that become increasingly cross-linked by lysyl oxidase enzymes and 
increase the tensile strength of the ECM (158).  The relative contribution of type I and type III 
collagen fibers and the degree of cross-linking can have a significant impact on the mechanical 
properties of the ECM (68).  While the exact origin of myofibroblasts in the heart remains 
controversial (134), the generally accepted hypothesis is that resident fibroblasts within the 
cardiac interstitium are prompted by environmental stimuli to proliferate and transdifferentiate into 
myofibroblasts.  During the resolution of normal tissue repair processes, active myofibroblasts 
revert back to either quiescent fibroblasts or undergo cellular apoptosis to allow for proficient 
wound healing (81, 101).  Disruption of this physiological process, either through overactive ECM 
production due to persistent hyperactive myofibroblast phenotype (156) or through defects in 
ECM degradation (185), results in pathological accumulation of ECM proteins, resulting in tissue 
fibrosis.  Fibrosis within a dynamic organ such as the heart can have adverse effects causing 
abnormal tissue stiffness, reduced myocardial perfusion, defective electrical signalling and 
arrhythmias along with impaired cardiac contraction and relaxation (88, 176, 220).   
In response to injurious insults, modulation of gene expression in tissue resident or infiltrating 
cells is essential to facilitate wound healing and appropriate myocardial remodeling (35, 117, 
128).  Considering heart failure has such a complex etiology, including a genetic and 
environmental input, it is crucial that we understand the mechanisms that regulate gene 
expression.  This is particularly important as alterations in these mechanisms could be 
contributing to the sustained aberrant cellular phenotype (i.e.  pro-hypertrophic, pro-fibrotic and 
pro-inflammatory phenotype) of cells that are implicated in driving pathological remodeling and 
promoting heart failure (Figure 1).  In this regard some clues are provided by studies of cardiac 
development.  Modulation of gene expression is crucial during normal cardiac development and it 
is of particular interest that during myocardial disease the damaged heart undergoes re-induction 
of the fetal gene program including re-expression of natriuretic factors (Nppa and Nppb), beta (β)-
myosin heavy chain (Myh7) and alpha-skeletal actin (63).  These data suggest that aberrant 
wound-healing may involve cell type-specific alterations at the level of gene-specific transcription 
factors that occur on top of epigenetic mechanisms such as DNA methylation and histone 
modification that influence global gene expression.  
 
DNA Methylation 
DNA methylation is a cellular process that involves the covalent attachment of a methyl residue to 
the carbon five prime position on a cytosine ring resulting in the formation of 5-methylcytosine 
(5MeC).  This process mainly occurs in palindromic cytosine-(phosphate)-guanine dinucleotides 
(CpGs) throughout the genome, with the majority (60-80%) of these in somatic cells being 
methylated (303).  Roughly 10% of CpGs are clustered together in regions known as CpG islands 
(CpGi’s) and are associated with approximately 70% of annotated mammalian gene promoters 
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(287).  These CpGi’s are GC rich, roughly a thousand base pairs long and generally are 
unmethylated, facilitating transcriptional activity (78).  CpGi’s are flanked by CpG shores and 
shelves, which are < 2 kb or > 2 kb from CpGi’s respectively and generally display dynamic 
changes in DNA methylation.  Three DNA methyltransferase (DNMT) enzymes (DNMT1, 
DNMT3A and DNMT3B) are involved in methylating DNA, using the methyl donor, S-
adenosylmethionine (SAM) to form 5MeC.  DNMT1 is involved in the maintenance of established 
DNA methylation (294) whereas DNMT3A and DNMT3B carry out de novo DNA methylation 
(246).  DNA methylation regulates gene expression through transcriptional repression both 
directly and indirectly.  DNA methylation can directly interfere with transcription factor binding to 
recognition sites in the promoter region (72) (Figure 2).  Indirect inhibition of gene expression can 
result through the recruitment of methyl-CpG-binding proteins such as methyl-CpG-binding 
protein (MeCP) 1 and 2 and methyl-CpG-binding domain protein (MBD) 1, 2, 3 and 4.  
Recruitment of these proteins promotes the interaction of co-repressor complexes with 
methylated DNA through their methyl-CpG-binding domain motif, leading to a transcriptionally-
repressed chromatin state and subsequent gene silencing (72, 132). 
While it was initially considered to be a persistent stable epigenetic mark, it is now apparent that 
DNA methylation is more dynamic in nature and can be reversed.  Removal of DNA methylation 
can occur through oxidation of 5MeC to 5-hydroxymethylcytosine (5hMeC) which is facilitated by 
the ten-eleven translocation (TET) family of enzymes (TET1, TET2 and TET3) (Figure 2).  The 
methylation mark is removed from the cytosine as 5hMeC undergoes deamination and 
subsequent base excision repair by thymine DNA glycosylase (173).  Emerging evidence is 
suggesting that rather than being an intermediate product of DNA demethylation, 5hMeC may 
itself function to regulate gene expression (54, 362).  Development of techniques such as 
isotope-based liquid chromatography mass spectrometry, glucosyl tagging and TET-assisted 
bisulfite sequencing (TAB-seq) has enabled researchers to determine the absolute levels and 
enrichments of 5hMeC within cells (255, 382). 
Intragenic methylation within the gene body and transcriptional regions is involved in gene 
regulation and alternative splicing (131).  The exact functional contribution that methylation of 
gene bodies has on governing gene expression is unclear with varying results reported within the 
literature.  Some reports highlight increased transcriptional activity that is associated with 
hypermethylation within the gene body (19, 93, 269, 378), whereas hypomethylation is 
accompanied with reduced gene expression (297).  Certain studies demonstrate the opposite, 
where increased gene expression is mirrored by demethylation of gene bodies (109, 194).  The 
exact relationship between gene body methylation and gene expression is not fully understood; 
however its role in modulating gene expression could have different consequences in different 
cellular contexts (194, 214). 
DNA Methylation in Heart Failure 
Involvement of DNA methylation in the failing heart is becoming increasingly apparent (Table 2).  
Analysis of whole genome bisulfite sequencing (WGBS) data sets across human cell and tissue 
types has identified tissue-specific differentially methylated regions (397).  Furthermore, regions 
with cardiac-specific DNA methylation patterns were shown to be enriched for single nucleotide 
polymorphisms (SNPs) linked to cardiovascular diseases in genome-wide association studies 
(397).  Numerous preliminary studies are demonstrating alterations in DNA methylation within 
cardiac tissue from patients with chronic heart failure.  Movassagh et al. investigated the global 
methylation profiles in cardiac tissue from a small cohort of patients with end stage heart failure 
(n=16), comparing them to non-diseased hearts (n=8) (230).  They found that there was a global 
reduction in CpGi methylation at promoter regions which in parallel also showed increased 
methylation at intragenic regions in patients with cardiomyopathy.  This was shown to correlate 
with areas of increased transcriptional activity.  Genes that were globally down-regulated in 
patients with cardiomyopathy were not found to be significantly correlated to increased 
methylation at the promoter regions.  One gene of interest that was found to have an enrichment 
of CpGi methylation in cardiac disease versus controls was the transcriptional activator Dux4.  
Hypermethylation of the Dux4 locus corresponded to a downregulation in its expression in failing 
hearts (230).  Previous work carried out by the same research group, using immunoprecipitation 
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of methylated DNA followed by methylation array analysis, demonstrated differential methylation 
at three gene loci (platelet endothelial cell adhesion molecule 1 (PECAM), Rho GTPase activating 
protein 24 (ARHGAP24) and angiomotin-like protein 2 (AMOTL2)), implicated in angiogenesis, in 
patients with end stage cardiomyopathy (229).  Differential methylation was shown to correlate 
with gene expression with reduced expression of PECAM as a result of promoter methylation, 
increased gene expression due to AMOTL2 promoter hypomethylation and hypermethylation of 
the ARHGAP24 gene body (229). 
Genome wide assessment of methylation profiles has also indicated aberrant CpGI methylation 
differences between idiopathic dilated cardiomyopathy (DCM) patients and controls (121).  The 
study highlighted two genes of interest, LY75 (CpGi hypermethylation) and ADORA2A (CpGi 
hypomethylation), where altered CpGi methylation was correlated with an abnormal reduction in 
gene expression (121).  In silico analysis revealed that CpGi hypomethylation in the ADORA2A 
gene promoter region is associated with the binding site for the transcriptional repressor CTCF, 
which could potentially account for why hypomethylation resulted in reduced gene expression.  In 
vivo validation of reduced expression of these genes in a zebrafish model showed development 
of cardiac dysfunction and heart failure (121).  Alterations of DNA methylation levels have also 
been reported in ischemic heart disease.  Hypomethylation of long interspersed nuclear element-
1 (LINE-1), a highly repeated and widely interspersed human retrotransposon) in mixed cell 
populations from patient blood samples was associated with ischemic heart disease and stroke 
(16).  LINE-1 elements were also found to be hypomethylated in patients with the congenital heart 
defect Tetralogy of Fallot (299) and while not found to be significantly correlated, patients with 
Tetralogy of Fallot displayed reduced expression of the DNA methylating enzymes DNMT1, 
DNMT3A and DNMT3B (298).  These LINE-1 elements are usually methylated in the majority of 
normal tissues (51).   
Global changes in DNA methylation have also been shown to play a role in the progression of risk 
factors that contribute to heart failure development (390) such as hypertension (304, 341, 360)), 
obesity and type 2 diabetes (T2DM) (74, 180, 336, 368), and atherosclerosis (49, 133).  In the 
context of hypertension, a recent genome-wide association and replication study by Kato et al., 
involving 320,251 people of East Asian, European and South Asian origin, identified genetic 
variants at 12 new loci to be associated with blood pressure phenotype (162).  They identified 
variants in genes involved in both vascular smooth muscle (IGFBP3, KCNK3, PDE3A and 
PRDM6) and renal (ARHGAP24 (previously mentioned above), OSR1, SLC22A7 and TBX2) 
function that are associated with methylation at multiple CpG sites, using both a 450K methylation 
array and targeted bisulfite sequencing.  These genetic variants identified along with previously 
known variants were shown to predict increased left ventricular mass, circulating levels of N-
terminal pro b-type natriuretic peptide (NT-proBNP), and both cardiovascular and all-cause 
mortality (162).  This study indicates that DNA methylation may be the cellular process that links 
sequence variation and blood pressure regulation, suggesting that aberrant changes in DNA 
methylation can have pathological consequences for the heart.   
 
Pharmacological Inhibition of DNA Methylation 
Another aspect that highlights the involvement of DNA methylation in aberrant cardiac remodeling 
has been revealed through studies showing the therapeutic benefits of DNMT inhibitors in 
preclinical models of heart failure.  5-azacytidine (5aza or Vidaza) and its more potent deoxy 
derivative, 5-aza-2-deoxycytidine (5azadC or Decitabine), are DNMT inhibitors that are approved 
by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for 
the treatment of myelodysplastic syndromes (MDS) and Acute Myeloid Leukaemia (237).  These 
demethylating agents are cytosine analogues and act by incorporating into DNA, and also RNA in 
the case of 5aza, forming tight covalent complexes with DNMT enzymes preventing their 
enzymatic activity and promoting their degradation (113).  5aza has previously been shown to 
have both anti-hypertrophic and anti-fibrotic actions in the Spontaneously Hypertensive Rat 
(SHR) model of HTN-induced heart failure (351).  Reduction of pathological remodeling after 
treatment with 5aza associated with an improvement in cardiac structure and function, measured 
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by reduced LV mass and improved ejection fraction, compared to untreated SHR’s (351).  
Another study assessing the effect of 5azadC in rats with norepinephrine-induced cardiac injury 
demonstrated that treatment with 5azadC reduced catecholamine-induced DNA hypermethylation 
(363).  By Langendorff preparation of the isolated hearts, the authors demonstrated various 
beneficial outcomes with 5azadC treatment including a reduction in left ventricular mass, 
improved cardiac contractility, decreased ROS production and reversed norepinephrine-induced 
changes in the expression of myotrophin and FHL2 (363).  Other experimental non-nucleosidic 
small molecular inhibitors of DNA methylation such as RG108 (274) have been shown to improve 
contraction and relaxation in an in vitro engineered heart tissue model after afterload 
enhancement.  The beneficial effect of these agents on aberrant cardiac remodeling in preclinical 
models has been demonstrated, yet the precise effect of these DNMT inhibitors on the different 
cell types of the heart involved in remodeling remains unknown.   
 
Histone Modifications 
Chromatin structure can play an important role in the regulation of gene expression and has been 
extensively studied.  Chromatin is composed of a basic structure known as the nucleosome, 
~145–147 bp of DNA wrapped around  a wedge-shaped compact histone octamer composed of 
two copies each of the histone proteins H2A, H2B, H3 and H4 (398).  The core histone proteins 
have amino -terminal tails which project out and make contact with adjacent nucleosomes and 
function as the principal sites for post-translational modifications (PTMs) (198).  These are small 
chemical modifications to the amino acid side chains that are added and removed by a multitude 
of highly specific enzymes.  These PTMs include acetylation, methylation, phosphorylation, poly-
ADP-ribosylation, ubiquitination, deimination and sumoylation (22, 179).  Modification at specific 
positions within histone tails can affect both the histone-DNA interactions and inter-nucleosomal 
interactions, facilitating remodeling of the chromatin structure and influencing the accessibility of 
transcriptional machinery binding to the DNA for active gene transcription (32).  Two of the most 
well studied PTMs are histone acetylation/deacetylation and histone methylation/demethylation 
(Figure 3).  Histone modifications are known to play a crucial role in cardiac development (211, 
340) and therefore it is not surprising that alteration of these modifications contributes to 
pathological remodeling within the heart. 
 
Histone Acetylation in Heart Failure 
Histone acetylation is the process by which acetyl groups are added to ε-amino group of lysine 
side chains and is catalyzed by the histone aceytltransferase enzymes (HATs), using acetyl 
coenzyme A as a cofactor (22).  There are 17 human HATs that are divided into five families 
based on sequence analysis.  These include the GCN4-related N-acetyltransferase (GNAT) 
family (for example NAT6, GCN5 and HAT1), the CBP/p300 proteins, the MYST family (including 
MOF, MOZ, MORF, TIP60), TAFII250 family (such as TAF1) and the steroid receptor coactivators 
(NCOA1, NCOA2, NCOA3) (209).  Addition of acetyl groups results in neutralization of the charge 
interaction between the negatively charged DNA backbone and the positively charged lysine 
residues, promoting relaxed chromatin conformation (euchromatin) and active gene transcription.  
Histone acetylation of lysine 9 (H3K9ac) and lysine 14 (H3K14ac) are marks that correlate with 
gene activation (335).  Acetylation marks are also associated with regulatory regions of the 
genome.  Enhancer regions of the genome are distal regions that stimulate gene transcription 
and can now be notably identified by acetylation of lysine 27 on H3 (H3K27ac) (268).  Removal of 
acetyl groups is carried out by histone deacetylase enzymes (HDACs) and results in chromatin 
condensation (heterochromatin) therefore repressing transcriptional competence (335).  There 
are 18 HDAC members that are categorized into four classes (I-IV) based on their structure, 
substrate specificity, cellular location and tissue-specific expression.  These include class I 
(HDAC1, 2, 3 and 8), class II (HDAC4, 5, 6, 7, 9, and 10), class III or sirtuins (SIRT1, 2, 3, 4, 5, 6, 
and 7) and class IV (HDAC 11) (75, 348).   
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The role of various HATs and HDACs in cardiac disease has been extensively studied.  The use 
of preclinical models of heart failure that harbour genetic defects, either deletion or 
overexpression of HAT or HDAC enzymes, along with the use of small molecule inhibitors of their 
function have collectively demonstrated their involvement in how the heart responds to cardiac 
injury, including cardiac hypertrophy and fibrosis (outlined in Table 3), previously reviewed in 
(115, 352, 364).   
One particular HAT that has been implicated in modulating heart failure is the acetyltransferase 
p300.  Levels and activity of p300 within myocardial biopsies from patients with ischemic, dilated, 
or unspecified end-stage cardiomyopathy was significantly increased compared to that of non-
failing control cardiac tissue (353).  Deficiency of p300 in mice is embryonically lethal and can 
result in cardiac abnormalities such as reduced ventricular trabeculation and weaker contractions 
with abnormal expression of myosin heavy chain and alpha-actinin proteins (380). 
Major emphasis has been placed on the role of HDACs in cardiac development and disease, 
focused mainly on class I and class II HDACs.  HDAC involvement in cardiac pathology is 
complex as different HDACs; even from the same class can have a differential influence on how 
the heart responds to cardiac injury through either promotion or attenuation of cardiac remodeling 
(115).  Levels of class I HDACs, HDAC1 and HDAC2, have previously been shown to be 
increased in both infarcted and non-infarcted myocardium of chronic heart failure (245).  Mice 
with global knockout for HDAC2 that received catecholamine-induced cardiac damage did not 
develop cardiac fibrosis, re-expression of fetal cardiac genes (Nppa, Myh7 and Acta1) or cardiac 
hypertrophy (330).  HDAC2 deficient mice were also protected from hypertrophy in response to 
transaortic constriction (TAC)-induced pressure overload, suggesting that HDAC2 plays a role by 
promoting aberrant cardiac remodeling (330).   
Class II HDACs, HDAC5 and HDAC9 demonstrate a cardiac protective role both in normal hearts 
and in response to cardiac injury.  Evidently, mice deficient in HDAC5 (53) and HDAC9 (386) 
were found to have age-dependent cardiac hypertrophy even in the absence of any cardiac 
injury.  In  the setting of pressure overload, these null mice displayed an exaggerated 
hypertrophic response associated with the ability of these HDACs to interact with and repress 
transcription of MEF2 target genes involved in driving cardiac hypertrophy, such as Nppa and 
Nppb (53, 386).  Interestingly, double knockout of HDAC5 and HDAC9 resulted in severe 
embryonic cardiac abnormalities including ventricular septal defects and thin ventricular walls 
(53).  Polymorphisms in HDAC9 have also been linked to increased risk and severity of coronary 
artery disease (30, 125, 344).  Another member of the class II HDAC family, HDAC6, has 
previously been shown to contribute to cardiac systolic dysfunction through effects on sarcomeric 
proteins and impairing contractility of myofibrils (80).  In response to AngII infusion, HDAC6 KO 
mice developed similar levels of aberrant cardiac remodeling to wild type mice (fibrosis and 
hypertrophy) but retained preserved ejection fraction with increased myofibril force generation 
(80).  This indicates that HDAC6, while not involved with remodeling of the heart, can still 
contribute to cardiac dysfunction through impairing cardiac contractility.   
Class III HDACs or sirtuins are characterized by their requirement of nicotinamide adenine 
dinucleotide (NAD+) for their enzyme activity (7, 144, 331) and have been implicated in the 
pathogenesis of cardiovascular disease and heart failure previously reviewed in (213) (Table 4).   
 
Pharmacological Targeting of Histone Acetylation and Deacetylation 
Involvement of histone acetylation in aberrant cardiac remodeling has been demonstrated by 
numerous studies that portray the therapeutic benefit of pharmacological inhibition of HAT and 
HDAC activity in preclinical models of heart failure.  Curcumin or diferuloylmethane, a polyphenol 
that acts to inhibit p300 HAT activity, has been shown to attenuate cardiac remodeling in rat 
models of hypertensive heart disease and MI (225, 226).  Inhibitors of HDAC activity (HDACi) are 
categorized into four groups; hydroxamates (Trichostatin A (TSA), suberoylanilide hydroxamic 
acid (SAHA)), benzamides (Entinostat), cyclic peptides (depsipeptide, also known as romidespin) 
and aliphatic acids (e.g.  Valproic acid) (365).  They can also have both broad inhibitory actions 
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and inhibit several classes of HDACs, such as SAHA and TSA, whereas others can selectively 
inhibit specific classes of HDACs such as apicidin, depsipeptide and SK7041 which are selective 
class I HDACis (236, 365) and specific for HDAC enzymes such as MPT0E014, a selective 
inhibitor of HDAC1, 2 and 6 (182).  HDAC inhibitors have demonstrated therapeutic benefit in 
numerous preclinical models of heart failure (352), showing a reduction in hypertrophy (106, 164, 
177, 248), fibrosis (148, 160) and inflammation (1, 216) resulting in improvements in cardiac 
function.  Recent data investigating the role of HDAC3 demonstrated that a selective inhibitor, 
RGFP966 prevented diabetic cardiomyopathy in a preclinical model of diabetes, with treated 
animals displaying a sustained reduction in inflammation, oxidative stress and cardiac fibrosis 
(369).  This work indicated that HDAC3 inhibition enhanced acetylation at the promoter region of 
the nuclear phosphatase DUSP5 gene resulting in its increased expression and ability to block 
activation of ERK1/2 activity (369).While three HDAC inhibitors have been FDA-approved (SAHA, 
romidespin and belinostat) for the treatment of cancers, such as T-cell lymphoma (228), none 
have yet received approval for the treatment of heart failure.  Activators of class III HDAC/Sirt 
activity, such as resveratrol, have also demonstrated beneficial effects on aberrant cardiac 
remodeling which seem to be independent of reducing cardiac injury.  SHR rats demonstrated a 
significant reduction in cardiac hypertrophy with improved cardiac function when treated with 
2.5mg/kg/day for 10 weeks (328).  The beneficial effects of resveratrol have been demonstrated 
in other pre-clinical models of heart failure (272, 323) and are thought to be due to reducing 
oxidative stress and preserving mitochondrial function. 
 
Histone Methylation and its Role in Heart Failure 
The process and consequences of histone methylation are more complex than acetylation.  
Methylation can occur on both lysine and arginine residues; residues can be methylated to 
different degrees (mono-, di- or tri-methyl for lysines and mono- or di-methyl for arginine) and 
depending on the residues that are methylated and the degree of methylation, gene transcription 
can either be repressed or augmented (178, 179, 290).  Currently it is known that histone 
methylation is a dynamic process.  Addition of methyl groups is carried out by methyltransferase 
enzymes, including the SET-domain-containing family and the disruptor of telomeric silencing 1-
like (DOT1L)/KMT4 family.  Previously, methylation of histones was considered a relatively stable 
epigenetic mark however the discovery of histone demethylase enzymes, which catalyse the 
removal of the methyl groups, demonstrated that histone methylation is a highly dynamic 
modification (300).  The two main families of demethylase enzymes are the LSD demethylases 
(LSD1/KDM1A and LSD2/KDM1B) and the Jumonji C-domain containing demethylases (JMJDs) 
(34, 300).  Methylation at specific lysine residues on histone protein 3, H3K4, H3K26 and H3K79 
are associated with active gene transcription whereas methylation at H3K27, H3K9 and H3K20 
are associated with transcriptionally silenced heterochromatin (178).  Tri-methylation of H3K36 
(H3K36me3) is normally found in the gene bodies of actively transcribed genes, however it also is 
associated with transcriptional repression (338).  Protein complexes that also act to modify 
chromatin structure through regulation of histone methylation include the Trithorax Group (TrxG) 
and the polycomb group (PcG) complexes (291).  TrxG complex promotes gene transcription 
through their H3K4 trimethylase activity, whereas PcG complexes have H3K27-specific 
trimethylase activity (such as Enhancer of zeste homolog 2 (EZH2) activity in the PcG2 complex), 
silencing gene transcription (291).  Both of these complexes have been shown to be critical for 
normal cardiac development and function (343). 
Alterations in histone methylation have been previously documented in failing human and rodent 
hearts (Table 5) (9, 137, 159, 334, 388).  Using chromatin immunoprecipitation (ChIP) coupled to 
pyrosequencing, Kaneda and colleagues have demonstrated marked differences in tri-
methylation for both K4 and K9 residues of histone H3 in both human heart failure and Dahl salt-
sensitive rat cardiac tissue (159).  Their analysis revealed enrichment of genes involved in 
signalling pathways related to cardiac function, such as calcium signalling, synaptic long-term 
regulation, G protein coupled and nitric oxide signalling, located close to these methylation marks, 
especially H3K4me3 (159).  The PAX interacting (with transcription-activation domain) protein 1 
(PTIP)-associated HMT complex, which contains PTIP, cofactors Ash2L, RbBP5, WDR5, the 
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KDM6A lysine demethylase and the SET domain containing methyltransferases KMT2B and 
KMT2C, are important in regulating H3K4me3 marks at actively expressed genes (253).  Studies 
have demonstrated the importance of these complexes in cardiac structure and function as 
reduction in H3K4me3 marks in the heart can result in aberrant calcium handling and ventricular 
arrhythmias upon β-adrenergic stimulation (309) while promoting maladaptive cardiac remodeling 
in pressure overload (308). 
Changes in methylation of histones have previously been implicated with re-expression of fetal 
genes in the failing heart (137).  Decreased H3K9 methylation and binding of Heterochromatin 
protein 1 in the promoter regions of Nppa and Nppb was found to be associated with their 
increased expression in failing human myocardium (137).  Upregulation of JMJDs (JMJD1A, 
JMJD2A, and JMJD2B) was also apparent in this study, with expression of JMJD1A positively 
correlating with reactivation of fetal genes, Nppa and Nppb (137).  Interestingly, this study also 
noted that recruitment of JMJD2A to the promoter region of Nppa was only found to be increased 
in ischemic cardiomyopathy and not in dilated cardiomyopathy (137).  Levels of JMJD2A have 
also been found to be augmented in patients with hypertrophic cardiomyopathy, suggesting that 
both levels and recruitment of demethylase enzymes can be altered in specific cardiac 
pathologies (388). 
Repression of Myh6 and Atp2a2 gene expression are changes established in the failing 
myocardium (137).  A study by Han and colleagues has highlighted the potential role of histone 
methylation silencing of Myh6 (334).  In a small cohort of human hypertrophic hearts linked to 
chronic hypertension and/or morbid obesity, changes in expression were mirrored by an 
enrichment of H3K9me2 in the Myh6 promoter region along with increased expression of G9a 
histone methyltransferase (334).  Other mechanisms could be due to lower levels of active 
methylation marks in its gene promoter.  Anagrisano et al., evaluated chromatin marks in the 
promoter regions of ATP2A2 and Myh7 genes, which were found to be aberrantly expressed in 
the hearts of mice subjected to chronic pressure overload (9).  Decreased transcriptional activity 
of ATP2A2 was associated with reduced H3K4me2 and increased repressive H3K9me2, 
H3K27me3, H3K36me2 marks with the opposite being found for Myh7, promoting its 
expression(9).  The increased methylation of H3K36 was associated with a reduction in lysine-
specific demethylase KDM2A at the ATP2A2 promoter (9). 
The abnormal gene expression demonstrated in both clinical and experimental models of heart 
failure, as a result of aberrant changes in histone methylation and demethylation, highlight the 
important role that this epigenetic process plays in the pathogenesis of cardiac disease.  Further 
insight into the cellular identity in which these changes take place could facilitate the development 
of novel targeted interventions to reverse these pathological changes and improve clinical 
outcome. 
 
Epigenetic Regulation of Cardiomyocyte Function 
Whilst cardiomyocytes are arguably the most important functional cell type in the heart they only 
account for 20-30% of the total cell population (277).  Cardiomyocytes are non-dividing, terminally 
differentiated cells that respond to pathological stress and injury by undergoing hypertrophy.  Due 
to their non-proliferative nature, and the assumption that new epigenetic modifications are 
primarily introduced into dividing cells, the influence of epigenetic modifications on regulating 
cardiomyocyte phenotype was generally overlooked.  Ex vivo investigation into the role of 
epigenetic regulation of myocyte function in both healthy and disease contexts has been limited 
on account of their terminally differentiated state and the fact that genomic DNA isolated from 
whole heart tissue contains such a variety of contributing cell types.  Recent evidence using 
various experimental animal models and novel methods to isolate cardiomyocyte nuclei from 
cardiac tissue (31, 109) is building a case for the idea that dynamic changes in epigenetic 
modifications plays a more significant role in regulating cellular function and response of the 
myocyte than previously thought. 
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DNA Methylation in Cardiomyocytes 
DNA methylation in myocytes was initially considered redundant due to their terminally 
differentiated state.  However, with de novo methylation (DNMT3A and DNMT3B) and 
demethylation (TET enzymes) which can alter methylation status and gene expression, it is now 
considered that DNA methylation can have the potential to modulate gene expression in postnatal 
cardiomyocytes (Table 6).  In order to investigate changes in DNA methylation, cardiomyocyte 
nuclei can now be isolated and purified from both rodent and human cardiac tissue by flow 
cytometry (fluorescent activated cell sorting) or magnetic-assisted nuclei sorting using an 
antibody against pericentriolar material 1 (PCM1) (31, 264).  PCM1 has been validated as a 
marker of cardiomyocyte nuclei in transgenic mice with cardiomyocyte-specific expression of 
histone H2B-mCherry (109).   
Dynamic changes in cardiomyocytes have been shown to occur during the postnatal period.  A 
study by Gilsbach et al., compared methylation profiles of cardiomyocytes from new-born and 
adult hearts (109).  They found that 121 genes gained and 313 lost methylation in the gene 
bodies during the postnatal period suggesting the role of de novo methylation.  The authors 
reported that genes hypermethylated postnatally were involved in muscle contraction, cardiac 
morphogenesis, cell differentiation and many other biological processes.  Investigating changes 
in DNA methylation that may occur in the functional adaptation of the heart during normal 
development, such as isoform switching in the expression of sarcomere proteins, the authors 
demonstrated the change from the fetal troponin I (Tnni1) to the adult troponin 3 (Tnni3) was 
accompanied by de novo methylation of Tnni1 and demethylation of Tnni3 with partial expression 
of Tnni1 being revived in adult cardiomyocytes.  While methylation changes in cardiomyocytes 
subjected to 3 weeks of pressure overload, were modest compared to those that were seen 
during myocyte maturation, at disease-associated differential methylation regions the methylation 
profile partially resembled that of fetal cardiomyocytes (109). 
To investigate the involvement of DNMT3 enzymes in cardiomyocytes and whether de novo 
methylation plays a role in altering cardiomyocyte response to injury, various groups have started 
to employ cardiac-specific DNMT knock out (KO) models, in particular with the DNMT3 isoforms.  
The crucial involvement of these enzymes in organism development has made creation of gene 
KO models to be very difficult.  DNMT3B homozygous KO mice die during gestation with severe 
developmental defects (246) and DNMT3A homozygous knockout mice appear normal at birth 
but become runted and die at about 4 weeks of age (246).  Cre-lox recombination has enabled 
the development of inducible DNMT3 isoform KO mice using cardiac specific promoters such as 
myosin heavy chain 6 (Myh6), troponin T (Tnnt2) and atrial myosin light chain (Myl7) (82).  
Cardiomyocyte-specific deletion of DNMT3B in 8 week old mice resulted in blunted hypertrophic 
responses accompanied with chamber dilation and decreased cardiac function when subjected to 
TAC and isoprotenerol (337).  Interestingly, mice that had sham surgery but had sustained loss of 
DNMT3B showed evidence of reduced contractility and chamber dilation resulting from 
widespread interstitial fibrosis and myo-sarcomeric alterations.  Differential methylation of three 
CpGs within intron 27 resulted in alternative splicing of Myh7 in mice with DNMT3B deletion 
subjected to pressure overload (337).   
Other groups have generated inducible DNMT3A/DNMT3B double KO mice, where 
cardiomyocytes lack the catalytic domains of DNMT3A and DNMT3B, to investigate whether de 
novo DNMTs in cardiomyocytes play a role in the response to pressure overload (243).  
DNMT3A/DNMT3B deletion had no effect on cardiac hypertrophy as double KO mice still had 
significantly increased LV mass, increased LV diameter, and interstitial fibrosis along with 
decreased ejection fraction and increased lung weight (243).  They carried out genome wide 
assessment of gene expression in ventricular tissue using an Illumina bead ChIP array to 
determine any genes that where differentially expressed in DNMT3A/DNMT3B KO mice, both 
with and without pressure overload.  In response to pressure overload they found 17 genes that 
showed differential expression as a result of genotype rather than disease state.  Three genes 
(Aldh1l1, Krt8 and Sclc9a3) were selected for pyrosequencing analysis based on their increased 
expression in the KO model, which was enhanced in response to pressure overload.  
Hypomethylation at CpG sites in promoter regions of these genes was found in cardiomyocytes 
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isolated from KO mice under sham conditions.  Expression of these genes was negatively 
correlated with methylation at these CpG sites in sham conditions with expression further 
increased in response to pressure overload (243).   
It is interesting to see differences in cardiac phenotypes found between the two different DNMT 
cardiomyocyte KO models in response to TAC.  While differences were noted between these 
models including KO of one DNMT compared to a double KO of two DNMT3 (3A and 3B) active 
isoforms along with differential timing of gene knockdown, the major finding from these studies is 
that de novo methylation is an active process in postnatal cardiomyocytes and can influence gene 
expression in these cells.  Recent work carried out by Fang et al., has highlighted the importance 
of DNMT3A in regulating cardiomyocyte gene expression, structure and function (90).  siRNA 
mediated downregulation of DNMT3A but not DNMT3B in embryonic cardiomyocytes resulted in 
abnormal structural and physiological properties including disruption in sarcomeric Z band 
organisation, impaired calcium signalling, decreased beat rate variability and loss of both 
contractility and contractile force (90).  These structural and functional myocyte defects were 
associated with differential gene expression in pathways involved in calcium signalling, 
endothelin-1, RAAS, β-adrenergic and insulin receptor signalling (90).  While Fang and 
colleagues have highlighted the importance of DNMT3A in developing cardiomyocytes, the other 
studies described above suggest that mice with cardiomyocyte-specific DNMT3A deletion mount 
a normal hypertrophic response to pressure overload. Further work is therefore needed to confirm 
whether DNMT3A is implicated in post-natal cardiomyocyte dysfunction after cardiac injury.   
While DNMT1 was generally considered to be redundant in cardiomyocytes because of their 
post-mitotic nature, it is becoming increasingly apparent that DNMT1 levels can be altered in 
response to cardiac injury, especially in states of metabolic stress.  DNMT1 expression was found 
to be elevated in cardiomyocytes exposed to high levels of glucose (57), homocysteine (55) and 
most recently an environmental pollutant, phenanthrene (142).  In these cells, the increased 
DNMT1 levels were accompanied by cellular dysfunction such as increased oxidative stress and 
myocyte hypertrophy (55, 142).  The potential role of DNA methylation in cardiomyocyte 
hypertrophy is further supported by evidence that pharmacological inhibition of DNMT activity in 
spontaneously hypertensive rats attenuates hypertension-induced increases in myocyte cross-
sectional area (351).  Interestingly, the microRNA, miR-133a, known to be involved in cardiac 
hypertrophy (48), was determined as an important regulator of DNMT1 expression.  Antagonizing 
the effects of miR-133a promoted expression of DNMT1 in cultured cardiomyocytes whereas 
overexpression resulted in transcriptional silencing (57).  Collectively these studies highlight that 
aberrant regulation of the maintenance methylating enzyme DNMT1 by non-coding RNAs in post-
mitotic cells such as cardiomyocytes may be involved in promoting cellular dysfunction in 
response to injury.   
The relevance of hydroxymethylation of DNA by TET enzymes has recently been implicated as a 
key cellular process that is involved in regulation of cardiomyocyte gene expression and cellular 
function in response to pressure overload (116).  Changes in hydroxymethylation distribution 
occur from the transition from enrichment of 5hMeC at intergenic regions in fetal cells to 
enrichment on the gene bodies of adult cardiomyocytes.  In the situation of pressure overload 
induced by TAC, the distribution of 5hMeC reverts back to that of the fetal pattern.  Reversion 
back to this fetal hydroxymethylation pattern, was found to be associated with upregulation of 
cardio-specific genes involved in extracellular matrix and actin skeleton organization and 
repression of genes related to energy metabolism including those involved in the tricarboxylic 
acid cycle and fatty acid oxidation (116).  In terms of 5MeC oxidation, TET2 was found to be the 
most abundantly expressed member of the TET family in cardiomyocytes and interestingly 
knockdown of TET2 led to alterations in 5hMeC at specific loci rather than global 
hydroxymethylation alterations.  The authors found that fetal genes were regulated by 
hydroxymethylation of DNA in hypertrophied cardiomyocytes, with genes such as Myh7 being 
regulated by genic and enhancer hydroxymethylation.  Reactivation of gene expression was 
associated with hydroxymethylation at intergenic enhancer regions whereas inhibition of TET2 
function by gene knockdown resulted in decreased hydroxymethylation at intragenic regions 
leading to in decreased expression of Myh7 (116). 
  13 
 
Histone Acetylation in Cardiomyocytes 
Numerous studies have implicated the ability of histone acetylation and deacetylation to influence 
the hypertrophic phenotype in cardiomyocytes (Table 7).  The involvement of HATs in promoting 
hypertrophy in cardiomyocytes was demonstrated using a model of catecholamine-induced stress 
in primary cardiac myocytes in culture (120, 374).  Over expression of p300 or CBP was shown to 
induce myocyte hypertrophy in vitro, with acetylation activity of these enzymes being increased in 
response to phenylephrine (120).  This phenylephrine-increased activity of p300 in myocytes has 
been shown to augment the DNA binding capacity of GATA4, a pro-hypertrophic transcription 
factor involved in driving increased cardiomyocyte size and sarcomere organization (5).  
Acetylation of the GATA4 transcription factor by p300 was also shown to increase myocyte cross-
sectional diameter in response to ischemic injury (219).  Other cardiomyocyte-specific 
transcription factors are also regulated by p300.  In response to pressure overload, cardiac-
specific over-expression of p300 was found to be associated with increased de novo acetylation 
of myocyte enhancer factor-2 (Mef2) with enrichment for transcripts in p300-regulated promoters, 
promoting cardiac hypertrophy and dysfunction (353).  This ability of p300 to induce hypertrophy 
of cardiomyocytes can be prevented by pharmacological inhibition of p300 activity (3, 226). 
HDAC enzymes are known to regulate myocyte growth responses to cardiac stress.  Studies 
looking at the role of HDAC2 in development and injury have yielded interesting findings (222, 
330).  Over-expression of HDAC2 under control of the Myh6 promoter resulted in significant 
myocyte hypertrophy.  One potential regulatory mechanism of HDAC2 to induce hypertrophy is 
through the PI3K-Akt-Gsk3beta pathway.  Over-expression of HDAC2 resulted in decreased 
expression of Inpp5f, increasing phosphorylation and inactivity of Akt, Pdk1 and Gsk3beta (330).  
Further gain- and loss-of-function investigations into the role of Inpp5f indicated that it plays a 
particularly important role in driving myocyte hypertrophy in response to cardiac stress (393).  
Myocytes deficient in Inpp5f did not experience any cardiac abnormalities under basal conditions; 
however, in the presence of adrenergic stimulation, displayed a significant hypertrophic response 
compared to wild type controls (393).  HDAC2 may also modulate other regulatory factors driving 
myocyte hypertrophy.  A study by Kee and Kook, using promoter mapping analyses of the Nppa 
promoter found that expression and binding of Krüppel-like factor 4 (KLF4) was significantly 
reduced upon HDAC2 activation by hypertrophic agonists (phenylephrine or partial aortic 
constriction) (163).  Furthermore, in vitro knockdown of KLF4 resulted in increased expression of 
Nppa, protein synthesis and stress fibre formation (163).  Interestingly, cardiac-specific loss of 
HDAC2 or HDAC1 had no impact on isoproterenol and pressure overload-induced hypertrophic 
responses (222).  Double knockout of both genes resulted in major cardiac defects such as 
cardiac arrhythmias and dilated cardiomyopathy, leading to death during the postnatal period 
(222) and was associated with altered expression of genes encoding myofibrillar proteins (Tnni1, 
Tnni2) and specific calcium channel subunits (CACNA1H, CACNA2D2).   
Other class I HDACs have also been implicated in regulating cardiomyocyte growth.  Cardiac-
specific deletion of HDAC3 resulted in apparent cardiac hypertrophy at 4 weeks of age and this 
was dramatically increased at 12 weeks of age with alterations in myofibril structure and 
mitochondrial structure (223).  Increases in expression of Nppa, Nppb and Acta1 were also seen 
in myocyte-specific HDAC3 KO mice (223).  The study concluded that the cardiac hypertrophy 
was associated with metabolic dysfunction with myocardial lipid accumulation and elevated 
triglyceride levels that were attributed to excessive activity of the peroxisome proliferator activated 
receptor (PPAR) α receptor (223).  Interestingly, transgenic overexpression of HDAC3 in 
cardiomyocytes did not show spontaneous cardiac hypertrophy or increased sensitivity to 
isoproterenol but did however result in increased myocyte proliferation at birth with decreased 
expression of negative regulators of cell cycle progression (329).  The involvement of class II 
HDACs in driving cardiomyocyte hypertrophy has been extensively reviewed previously (352).   
Pharmacological inhibition of HDAC enzymes has been shown to attenuate the pathological 
hypertrophic phenotype in cardiomyocytes.  Antos et al. assessed the hypertrophic response of 
primary cardiomyocytes when treated with HDACis (including TSA).  They found that HDACi 
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treatment resulted in blunted hypertrophic responses, showing reduced protein synthesis and 
inhibition of fetal gene re-expression (10).  It has also been demonstrated that HDAC inhibition 
may provide a cardio-protective effect to myocytes/myoblasts in the case of ischemic injury (387).  
One potential mechanism by which the beneficial effect of TSA could be mediated is by activation 
of ubiquitination-dependent proteasomal degradation of HDAC4 through sumoylation (83).  
Collectively, these results are recapitulated in the numerous studies that have previously 
demonstrated anti-hypertrophic and cardio-beneficial effects of pharmacological inhibition of 
HDAC activity.  Evidence is also emerging to implicate the involvement of long non-coding RNAs 
(lncRNA) in the development of heart disease and cardiac dysfunction via regulation of histone 
modifications.  One potential novel mechanism by which HDACis can reduce cardiac hypertrophy 
is through modulation of lncRNA expression (124).  A cluster of alternatively spliced transcripts of 
Myh7, known as Mhrts, have been shown to have cardio-protective effects through interaction 
with the helicase domain of Brg1 complex, which is known to induce pathological switch of 
Myh6/7 gene expression in response to stress (124).  Under myocardial stress situations, such as 
pressure overload, it was shown that the Brg1-HDAC-PARP chromatin repressor complex inhibits 
the transcription of Mhrt, promoting cardiomyocyte hypertrophy (124).  Use of the HDACi, TSA, 
restored expression of Mhrt, preventing Brg1 from recognizing its chromatin targets (124).   
Sirtuins (Class III HDACs) have also been implicated in modulating the hypertrophic 
cardiomyocyte phenotype.  Cardiomyocyte-specific deletion of SIRT6 in adult mouse hearts 
resulted in significant cardiac hypertrophy, measured by echocardiography and histology.  The 
mechanism by which Sirt6 appears to act as a negative regulator of cardiac hypertrophy is 
through both deacetylating H3K9 and negatively regulating the expression of Insulin-like growth 
factor (IGF) signalling–related genes by suppressing the transcriptional activity of c-Jun (316).  
Other Sirtuins have also been implicated in regulating cardiomyocyte hypertrophy including Sirt1 
(314) and Sirt3 (315).  Altogether, these studies highlight the potential of acetylation and 
deacetylation in regulating the hypertrophic phenotype in cardiomyocytes in response to cardiac 
injury. 
 
Histone Methylation in Cardiomyocytes 
The process of histone methylation is crucial for normal cardiomyocyte development, 
homeostasis, and response to injury (Table 8).  This was demonstrated by Wamstad and 
colleagues when they induced cardiomyocyte differentiation from embryonic stem cells in a 
stepwise manner and found dynamic changes in histone modifications, H3K4me1, H3K4me3 and 
H3K27me3 that govern cardiomyocyte differentiation (340).  Methyltransferase enzymes such as 
DOT1L have been demonstrated to mediate H3K79me2 modifications, which are critical for 
regulation of gene expression during cardiomyocyte differentiation and maturation (252).  Further 
importance of these modifications is that de novo mutations in genes involved in production, 
removal or reading of H3K4me and H3K27me contribute to the development of severe congenital 
heart disease (384). 
Alterations in global histone methylation have been associated with hypertrophic response in ex 
vivo isolated cardiomyocytes (252).  Cardiomyocytes isolated from the hearts of mice that 
experienced one week of TAC-induced pressure overload demonstrated altered epigenetic 
profiles at enhancer and promoter regions with dynamic and locus-specific alterations in both 
active (H3K4me3 and H3K79me2) and repressive (H3K9me2, H3K9me3, and H3K27me3) 
histone marks (252).  These histone marks in the promoter regions correlated with expression of 
a large group of genes in cardiomyocytes that were differentially expressed (325 genes out of 
1109) as a result of pressure overload (252).   
Activation of gene expression in response to cardiac injury in cardiomyocytes is essential to 
maintain cardiac integrity.  Using a cardiomyocyte-specific KO model for PTIP-associated HMT 
complex, Stein and colleagues demonstrated that different cardiac phenotypes occur in response 
to different cardiac insults, with H3K4me3 methylation being an important regulator (308, 309).  
PTIP KO mice that experienced β-adrenergic stimulation by isoproterenol and caffeine developed 
ventricular arrhythmias and abnormal calcium handling, but did not experience cardiac 
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hypertrophy (309).  Interestingly, however, in TAC-induced pressure overload, PTIP KO mice 
experience maladaptive cardiac remodeling with significant cardiac dilation and impaired cardiac 
function.  These aberrant changes were found to be accompanied by altered gene expression of 
ADRA1A, ADRA1B, JUN, ATP2A2, ATP1A2, SCN4B, and CACNA1G suggesting that precise 
regulation of these genes in cardiomyocytes is important for proper adaptive responses to injury. 
The role of histone demethylation in the hypertrophic response of cardiomyocytes has been 
clearly demonstrated by Zhang and colleagues (388).  In the absence of injury, mice either 
lacking or over-expressing JMJD2A in cardiomyocytes showed normal cardiac morphology and 
function (388).  However, in response to pressure overload, overexpression of JMJD2A conferred 
an exacerbated hypertrophic response and the opposite was seen with deletion of JMJD2A in 
cardiomyocytes, which attenuated hypertrophy with improved cardiac function (388).  The authors 
found that JMJD2A promotes myocyte hypertrophy through binding to the promoter of four-and-a-
half LIM domains protein 1 (FHL1), increasing its expression via transcription factors such as 
serum-response factor and myocardin (388).  Interestingly other JMJD enzymes altered in human 
heart failure, such as JMJD1A have been shown in vitro to compensate for knockdown of 
JMJD2A in neonatal cardiomyocytes.  Knockdown of either JMJD1A or JMJD2A alone did not 
impact on the regulation of fetal gene expression (Nppa and Nppb) (137).  Double knockdown of 
both JMD1A and JMJD2A in neonatal cardiomyocytes resulted in increased H3K9me2 and 
H3K9me3 at the promoter regions of Nppa and Nppb, resulting in a moderate decrease in their 
expression (137).   
As expected the involvement of histone methylation in regulating gene expression in the failing 
heart is complex and involves orchestration and collaboration of other cellular processes that 
regulate gene transcription, including other epigenetic processes such as DNA methylation and 
non-coding RNAs, to drive a pathological hypertrophic myocyte phenotype.  Han et al, have 
demonstrated that transcriptional silencing of Myh6 in response to pressure overload is achieved 
in a step by step manner whereby the ATP-dependent chromatin remodeling complex, Brg1, 
recruit histone methyltransferases (G9a/Glp) which then recruit DNMT3A, leading to DNA 
hypermethylation and stable Myh6 repression (334).  The role of histone methylation in this 
cascade was demonstrated by doxycycline-inducible deletion of G9a in adult cardiomyocytes.  
G9a-deficient mice subjected to pressure overload displayed only mild hypertrophy at two weeks 
and went on to demonstrate significant improvement in both hypertrophy and cardiac function at 8 
weeks compared to littermate controls (334).  With these improvements, TAC-induced H3K9me2 
of Myh6 was significantly reduced as was binding of DNMT3A to the Myh6 promoter and CpG 
methylation (334).  LncRNAs have also been demonstrated to interact with chromatin remodeling 
complexes and modulate histone modifications for induction of cardiac hypertrophy in myocytes.  
A recent study published by Wang et al., has highlighted the role a lncRNA known as cardiac 
hypertrophy associated epigenetic reader (Chaer), which is located predominantly in the nucleus, 
expressed in cardiomycoytes and regulates the development of myocyte hypertrophy in response 
to cardiac injury (349).  Chaer-deficient mice displayed no functional or morphological differences 
in cardiac phenotype under basal conditions, and showed attenuation of pathological remodeling 
in response to TAC (349).  Suppression of phenylephrine-induced hypertrophy and expression of 
hypertrophic genes (Nppa, Myh7 and Acta1) was achieved after knockdown of Chaer in 
ventricular myocytes.  Overexpression of Chaer, even in the absence of beta-adrenergic 
stimulation resulted in enlargement of myocytes and increased expression of Myh7 and Acta1.  
The mechanism by which Chaer promotes hypertrophy is through its interaction with the PcG2, 
mediated by mTOR signalling, preventing it from binding to and carrying out H3K27 methylation 
at the promoters of hypertrophic genes (349).  These findings were demonstrated in both human 
and rodent cardiomyocytes suggesting a highly conserved mechanism of stress induced 
regulation of myocyte hypertrophy (349).   
 
Epigenetic Regulation of Fibroblast Function 
Fibroblasts are spindle shaped mesenchymal cells with oval nuclei that play a functional role in 
the development and maintenance of the structural and physiological integrity of organ systems in 
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the body.  While fibroblasts are found all over the body and are primarily involved in the 
production and turnover of ECM, in the heart these cells can also influence important 
physiological aspects including angiogenesis, contractility and cardiac electrophysiology (44, 262, 
306).Throughout the literature fibroblasts are usually identified by various cellular markers 
including surface markers (Discoidin domain receptor 2 (DDR2), Fibroblast surface antigen and 
Fibroblast activation protein 1 (FAP-1)), intracellular markers (αSMA, vimentin and Fibroblast-
specific protein 1 (FSP-1)) and secreted products (CTGF/CCN2  and Collagen I) which generally 
have been shown to be highly expressed by fibroblasts in the diseased heart (105).  
Unfortunately, specificity of these markers to cardiac fibroblasts remains an issue as they are also 
expressed by other cell types including endothelial cells, smooth muscle cells, lymphocytes and 
other mesenchymal cells including pericytes, as previously summarised by Ma and colleagues 
(199).  Initially, fibroblasts were considered to account for 60-70% of the total population of cells 
within the heart, however recently this figure has been revised with evidence suggesting that 
fibroblasts account for <20% of the total non-myocyte cardiac cell population (258).  None the 
less, fibroblasts are still a cell of great interest due to the role they play in wound healing and 
cardiac pathology. 
The functional abilities of cardiac fibroblasts are mediated through transdifferentiation into cardiac 
myofibroblasts that have high ECM synthetic abilities.  The exact origin of myofibroblasts in the 
heart is controversial, with various sources being hypothesized under stressful conditions 
including proliferation of resident cells (224), recruitment of bone marrow-derived progenitor cells 
(332), epithelial-to-mesenchymal transition (EMT) of epicardial cells (43) and endothelial-to-
mesenchymal transition (EndMT) of endothelial cells (4).  Regardless of the precise source of 
these cells, it is undisputed that, injurious stimuli including ischemia, reperfusion and mechanical 
stretch activate this phenotypic transition with fibroblasts becoming hyper-activated and adopting 
a pro-fibrotic myofibroblast phenotype.  Unlike in organs such as the skin, where the 
myofibroblasts are transient and undergo apoptosis after resolution of the normal wound healing 
processes (81), myofibroblasts have been shown to persist in the heart, months and even years 
after the initial cardiac injury (157, 357).  Evidently, ex vivo culture of fibroblasts from fibrotic 
environments demonstrates that these cells maintain their cellular characteristics and proliferative 
capacity (156).These cells are also known to become sensitised and can further release pro-
inflammatory mediators such as cytokines and chemokines which subsequently enhances 
pathological remodeling in the injured heart (262).   
Whether in the case of reparative fibrosis in myocardial infarction, reactive fibrosis in pressure 
overload or aging, the exact driving force behind this persistent hyperactive myofibroblast 
remains unknown.  What is known is that acquisition of the activated myofibroblast phenotype is 
accompanied by changes in gene expression (256).  Epigenetic mechanisms such as DNA 
methylation and histone modifications could therefore underpin this aberrant persistent cellular 
phenotype that ultimately contributes to the development and progression of cardiac failure. 
 
DNA Methylation in Fibroblasts 
Regulation of fibroblast phenotype and function by DNA methylation (Table 9) has been widely 
studied in numerous fibrotic conditions such as renal fibrosis, hepatic fibrosis, pulmonary fibrosis, 
cardiac fibrosis and systemic sclerosis.   
Within the heart several genes have been identified whereby methylation of their promoter 
regions modulates their expression and impacts fibroblast/myofibroblast function.  Xu et al. 
initially demonstrated that hypermethylation of the RAS Protein Activator Like 1 gene (RASAL1), 
which functions to inhibit Ras-GTP activity, along with its transcriptional silencing was found in 
both a mouse model of pressure overload and in human fibrotic heart tissue from patients with 
end-stage heart failure (366).  They found that this aberrant promoter methylation of RASAL1 
promoted EndMT of human coronary endothelial cells (366), can be induced by hypoxia and is 
mediated by DNMT3A (367).  Hypermethylation and transcriptional silencing of RASAL1 has 
been implicated in fibroblast activation and fibrogenesis in numerous fibrotic pathologies including 
hepatic stellate cells (HStCs) in hepatic fibrosis (206, 324), renal fibroblasts in renal fibrosis (27) 
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and human trabecular meshwork cells in glaucoma (215).  Silencing of RASAL1 expression 
through promoter hypermethylation is thought to be mediated through MeCP2(324).  Another 
gene that has been implicated in aberrant fibroblast activation and proliferation is Ras-association 
domain family 1 isoform A (RASSF1A), which functions as a tumour suppressor gene and is 
involved in the negative regulation of biological processes such as cell proliferation and cell 
survival (13).  RASSF1A has an important role in the heart as systemic knock out of the gene 
results in an exaggerated fibrotic response after pressure overload (79).  Interestingly, cell 
specific expression of this gene in the heart can have differential functional consequences, with 
loss of RASSF1A expression in cardiac fibroblasts advocating increased fibroblast proliferation 
and survival (79).  DNA methylation seems to implicated in the regulation of RASSF1A 
expression in fibroblasts, as PDGF-activated fibroblasts demonstrate increased levels of 
DNMT3A in combination with reduced levels of RASSF1A (325).  siRNA knockdown of DNMT3A 
restored RASSF1A expression and inhibited the pro-fibrotic phenotype (325).  Other examples of 
genes being epigenetically silenced by DNA methylation include the collagen suppressor gene 
FLI1 in dermal fibroblasts (346), PTCH1 in hepatic myofibroblasts (377)and Pck2 in pulmonary 
fibroblasts (377). 
With all fibrotic conditions, hypoxia is a unifying factor that is now appreciated to modulate 
fibroblast gene expression through DNA methylation.  Watson et al., have shown that hypoxia 
(1% oxygen) for 8 days induced global DNA hypermethylation in the genomes of cardiac 
fibroblasts.  DNA hypermethylation was mirrored with increased expression of DNMT enzymes 
(DNMT1 and 3B) along with fibrotic markers (collagen 1 and αSMA) (350).  Increased global DNA 
methylation induced by hypoxia has also been demonstrated in human pulmonary fibroblasts 
(273).  On a gene specific manner, hypoxia-induced reduction of Thy-1 expression in these 
fibroblasts was associated with hemi-methylation of its gene promoter.  Methylation of the Thy-1 
promoter in fibroblasts can also be induced by in vitro treatment with pro-fibrotic cytokines such 
as TGFβ1, which acts to increase DNMT activity (241).  Thy-1 deficient fibroblasts have 
previously been shown to be more resistant to apoptosis and have a fibrogenic phenotype (283). 
Most studies that find aberrant gene expression as a consequence of DNA methylation have 
demonstrated reversal by pharmacological inhibition of DNMT activity or through intrinsic 
demethylation processes.  The main DNMT inhibitor used in these investigations to reverse the 
hyperactive fibroblast phenotype is 5-azadC, whereby treatment of activated fibroblasts resulted 
in a reduction of the main fibrotic markers such as αSMA, collagen 1 or collagen 3 or a reduction 
in cell proliferation (215, 273, 324, 346, 350, 377).  Inhibition of DNMT activity by 5aza has also 
demonstrated anti-fibrotic action on activated fibroblasts.  In the context of the heart, inhibition of 
DNA methylation with 5aza resulted in a significant decrease in expression of collagen 1 and 3 in 
myofibroblasts derived from human ventricular cardiac fibroblasts (351).  Exposure of fibrotic 
human kidney and pulmonary fibroblasts to 5aza displayed similar in vitro results (27, 141).  Of 
note, attenuation of the fibrotic phenotype by 5aza in pulmonary fibroblasts was attributed to a 
reduction of bone morphogeneic protein (BMP)-endothelial cell precursor-derived regulator 
(BMPER) expression, which modulates TGFβ/BMP signalling by interacting directly with BMP’s 
(BMP-2, -4 and -6)(141).  BMPs are growth factors which exert diverse effects on target tissues 
with increased and decreased BMP signalling activity present in many cardiovascular diseases 
(227).  Reduced expression of BMPER could potentially lead to augmented levels and action of 
BMPs such as BMP-6, which has been previously shown to inhibit pro-fibrogenic gene expression 
in activated-HStCs and ameliorate hepatic fibrosis (11).  Other BMPs have also been shown to 
activate demethylation in fibroblasts.  Tampe and colleague induced Tet3-mediated 
hydroxymethylation and demethylation of the RASAL1 promoter by treating activated renal 
fibroblasts with BMP-7 (321).  In a different study by the same research group, demethylation of 
the RASAL1 promoter by DNMT inhibition with 5aza inhibited EndMT independently of an effect 
on TET expression (366).  The differential demethylation of RASAL1 seen in both studies due to 
DNMT inhibition or TET-mediated hydroxymethylation could be attributed to differential activation 
or repression of different molecular pathways or because of the different cell types investigated.  
Collectively, these studies highlight DNA methylation as an important cellular process in 
modulating the fibroblast/myofibroblast phenotype and that these established fibrotic 
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characteristics can be manipulated by pharmacological DNMT inhibition or through activation of 
intrinsic demethylation processes. 
 
Histone Acetylation in Fibroblasts 
Therapeutic intervention or genetic manipulation of the histone acetylation/deacetylation 
machinery has been shown to prevent the development of fibrosis and contribute to an overall 
improvement in cardiac function in preclinical models of heart failure (148, 160, 244, 245, 272, 
323, 330).  These agents are thought to impact the cellular function of fibroblasts due to various 
reasons including inhibition of proliferation and attenuating their ability to respond to both 
developmental and injurious cues.  The role of HATs and HDACs in fibroblasts is outlined in 
Table 10. 
Pan-HDAC inhibitors have demonstrated their anti-fibrotic properties on isolated activated 
ventricular fibroblasts.  Kong and colleagues were able to suppress collagen 1 synthesis and 
fibrogenesis by in vitro treatment with TSA (177).  Both HDAC1 and HDAC2 have been 
previously shown by Nural-Guvener et al., to be strongly expressed in fibroblasts in the ischemic 
myocardium of rats which experienced chronic myocardial infarction for 6 weeks (245).  Their 
work revealed that administration of the selective benzamide class I HDAC inhibitor, 
Mocetinostat, reduced expression of αSMA and other markers of active myofibroblasts including 
collagen III and MMP2.  Treatment of primary cardiac fibroblasts with Mocetinostat also 
upregulated p21/p53 and levels of cleaved caspase-3, which are involved in cell cycle arrest and 
apoptotic responses.  Further work carried out by that group has highlighted that the inhibitory 
action of class I HDACs on activated fibroblasts could be through modulation of the IL-6/STAT3 
signalling pathway leading to attenuation of their proliferation, migration and activation 
(244).Other potent HDAC inhibitors have also been shown to inhibit fibroblast activation.  
Treatment of primary cardiac fibroblasts with MPT0E014 inhibited cell proliferation, even in the 
presence of TGFβ and reduced expression of the Angiotensin-II type I receptor, a receptor known 
to activate a pro-fibrotic and pro-inflammatory fibroblast phenotype upon ligand binding of 
Angiotensin-II (160).   
Similar blunted myofibroblast responses after HDAC inhibition have been indicated from 
fibroblasts cultured and stimulated from other organ systems including the liver (242, 266), kidney 
(195), lung (119, 284) and skin (33, 275).  To determine the involvement of HDACs in the 
transdifferentiation of dermal fibroblasts to myofibroblasts with TGFβ, Glenisson and colleagues 
carried out siRNA knockdown of HDACs followed by activation with TGFβ.  They discovered that 
knockdown of HDAC4, HDAC6, and HDAC8 expression impaired TGFβ-induced αSMA 
expression, but repression of HDAC4 expression in particular returned levels of  αSMA back to 
control levels (110).  This work was supported by Guo et al., who showed that HDAC4 
knockdown resulted in attenuation of pulmonary myofibroblast activation (119).  The mechanism 
they concluded was that HDAC4 plays a role in myofibroblast activation by regulating TGFβ-
induced Akt phosphorylation (119).  Other reports have also deemed HDAC4 to be an important 
regulator of MMP9 and MMP13 expression upon myofibroblast transdifferentiation in hepatic 
fibrosis (266).   
Analysis of these HDAC inhibitors in these fibrotic disease contexts has highlighted putative 
genes that are abnormally regulated by deacetylation of histone proteins and may be linked to the 
development of an activated myofibroblast phenotype.  Russell et al., found that expression of 
SFRP1, an inhibitor of Wnt signalling, was restored in dermal keloid fibroblasts after treatment 
with TSA and was associated with a decreased expression of collagen and CTGF/CCN2  (279).  
Thy-1 expression, as previously described is regulated by DNA methylation in pulmonary 
fibroblasts and is also modulated by histone deacetylation.  Sanders et al., found that TSA 
treatment of fibrotic pulmonary fibroblasts partially restored expression of Thy-1 and aided in 
demethylation of its gene promoter leading to decreased expression of αSMA (284).  This study 
nicely demonstrates how epigenetic mechanisms interact together to regulate gene expression 
and function of fibroblasts. 
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With the majority of work focused on the role of HDACs in driving an abnormal myofibroblast 
response, evidence on a role of HATs in the promotion of a cardiac myofibroblast phenotype has 
been limited but is evident in other fibrotic disorders.  Fibroblasts derived from the skin of patients 
with systemic sclerosis express elevated levels of p300 compared to healthy fibroblasts.  
Furthermore, manipulating p300 levels in vitro revealed that Smad-dependent TGFβ activation of 
fibroblasts is dependent upon p300 (33).  Collectively these studies highlight that histone 
acetylation and deacetylation are clearly important in modulating fibroblast phenotype and 
function and have the potential to contribute to abnormal cardiac wound healing. 
 
Histone Methylation in Fibroblasts 
While it is becoming increasingly evident that changes in histone methylation and demethylation 
are present in heart failure, the exact contribution of these epigenetic enzymes to modulating the 
cardiac fibroblast phenotype and promotion of cardiac fibrosis is unknown.  Many of the studies 
investigating the involvement of histone methylation in development of the pro-fibrotic 
myofibroblast phenotype are centred in other fibrotic disease areas such as hepatic, pulmonary 
and renal fibrosis, but could shed some light onto the acquisition of the hyperactive myofibroblast 
phenotype in the injured and failing heart (Table 11). 
The G9a methyltransferase is evident as being a key player in renal, hepatic and pulmonary 
fibrosis.  TGFβ-induced phosphorylation of Smad3 was found to augment expression of G9a in 
activated rat interstitial kidney fibroblasts and induce expression of fibrotic markers αSMA and 
fibronectin (145).  These pro-fibrotic changes both in vitro and in vivo were abrogated by 
application of the selective G9a-methyltransferase inhibitor BIX01294, with a reduction in 
repressive H3K9me1 levels (145).  Similar therapeutic benefit through H3K9me1 suppression by 
G9a-methyltransferase inhibition has been also recently described in an in vitro model of 
peritoneal fibrosis (201).  Involvement of G9a in gene repression has also been reported in 
pulmonary fibrosis through H3K9 trimethylation of the anti-fibrogenic cyclooxygenase-2 (COX2) 
gene promoter (69).  Silencing of the COX2 gene in idiopathic pulmonary fibrosis patient-derived 
fibroblasts was also facilitated by interdependent action of DNA methylation and H3K27 
trimethylation by the lysine methyltransferase EZH2 (69).  Pharmacological inhibition of G9a-
methyltransferase by BIX01294 and EZH2 by 3-Deazaneplanocin A (DZNep) improved the 
phenotype of pro-fibrotic pulmonary fibroblasts by augmenting the expression of COX2 and its 
product prostaglandin E2 (69). 
Acquisition of the myofibroblasts phenotype by HStCs and development of hepatic fibrosis has 
been associated with global changes in histone methylation marks, with increased trimethylation 
of both H3K4 and H3K27 (254).  Complementary studies have been carried out to dissect the role 
of specific histone methyltransferases in creating this fibrotic myofibroblast phenotype.  ASH1 
methyltransferase has been proven to bind to the promoter regions of pro-fibrotic genes αSMA, 
TIMP-1, collagen-1 and TGFβ, facilitating active H3K4me3 marks and promoting active gene 
expression (254).  Furthermore, H3K27me3 repressive methylation marks in the 3’ exons of 
PPARy are known to induce transcriptional silencing and are created by the lysine 
methyltransferase EZH2 in active myofibroblasts (385).  Evidently, both genetic knockdown and 
pharmacological inhibition of EZH2 activity by DZNep reduced fibrotic gene expression, inhibited 
morphological changes and myofibroblast proliferation (385).  It seems that the expression and 
recruitment of these lysine methyltransferases, and their ability to promote and establish a 
myofibroblast phenotype and tissue fibrosis, is regulated by MeCP2 (254, 385).  Whilst DZNep 
inhibition of EZH2 shows therapeutic promise, a major problem faced with any epigenetic therapy 
is to therapeutically target specific cells.  Zeybel and colleagues have recently shown promising 
data in which they have been able to specifically target hepatic myofibroblasts in vivo using a C1-
3-liposomal vector carrying DZNep (385).  Treatment with targeted DZNep displayed 
improvements in hepatic collagen deposition along with reduced expression of fibrotic markers 
collagen 1A1, CTGF/CCN2 , and angiopoetin 1 in the hepatotoxic carbon tetrachloride model of 
hepatic fibrosis (385). 
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JMJD enzymes facilitate the removal of methyl groups from lysine residues on histone proteins 
through oxidative demethylation.  Expression of several histone demethylating enzymes including 
KDM2B, JMJD1A, JMJD2B, JMJD2C, JMJD3 and KDM5B has been previously shown to be 
inducible in hypoxic conditions through HIF-1α (186, 282).  This suggests that indeed when the 
myocardium becomes hypoxic, either due to perfusion defects or increased oxygen consumption 
by infiltrating inflammatory cells and metabolically active fibroblasts, active lysine demethylation 
can occur with subsequent regulation of gene expression.  Removal of H3K4me3 marks by the 
histone demethylase KDM2B has been highlighted as an important regulator of fibroblast 
function.  Over expression of KDM2B in murine embryonic fibroblasts was associated with 
dynamic transcriptomic changes of 264 genes involved in various cellular processes including 
inflammation (chemokines CCL2, CCL5, CCL7, and CXCL10), metabolic processes (Crabp2 and 
Ripbk3) and ECM production (Col2A1) (151).  Chemokines are signalling molecules that play an 
important role in the recruitment of inflammatory cells to the site of tissue injury to initiate the 
wound healing process.  Sustained secretion of these signalling proteins by cardiac fibroblasts, 
due to alterations in histone demethylation, can result in persistent inflammatory cell recruitment 
to the heart.  Consequently, this may exacerbate a vicious cycle of inflammation and hypoxia, and 
lead to further tissue damage, aberrant wound healing and cardiac fibrosis.   
 
Epigenetic Regulation of Immune Cell Function 
Immune cell infiltration into the damaged heart is a major contributor for stimulating cardiac 
remodeling, due to the release of inflammatory mediators and the phagocytic removal of 
damaged tissue within the heart.  Inflammatory cells rely upon their ability to degrade ECM in 
order to infiltrate cardiac tissue and also play a major role in driving fibroblast production of new 
ECM during the wound healing process.  Healthy restoration of normal tissue architecture 
requires a delicate balance between pro-inflammatory, pro-resolution, and pro-wound healing 
actions of immune cells.  The microenvironment of the damaged heart can influence the function 
of tissue-resident immune cells as well as the recruitment and behaviour of infiltrating immune 
cells.  
Neutrophils are polymorphonuclear granulocytes that play a critical role in innate immunity. They 
are the first-line immune cells recruited to sites of injury or infection. The role of neutrophils in 
myocardial infarction is well documented (99).  In response to acute cardiac injury, recruited 
neutrophils become activated by danger-associated molecular patterns (DAMPs) such as 
liberated intracellular ATP, mitochondrial DNA, heat shock proteins and fibronectin fragments (73, 
200). Once activated, neutrophils release their granular contents including ROS, cytokines, 
chemokines and MMPs (MMP8 and MMP9), which function to drive inflammation and tissue 
remodeling after injury (200).  Whilst it is well established that neutrophils play an important role 
in tissue responses to acute injury their contribution to aberrant cardiac remodeling in the setting 
of chronic injury such as that seen in hypertensive heart disease is unclear.   
Monocytes are involved in various physiological processes including inflammation and tissue 
remodeling.  They are a major constituent of both the innate and adaptive immune response.  
Monocytes are derived from bone marrow-derived progenitor cells and are recruited to the site of 
injury where they differentiate into pro-inflammatory M1 or “classical” macrophages, M2 or 
“alternative” macrophages or dendritic cells, depending upon specific signalling cues (62, 114).  
M1 macrophages are involved in pro-inflammatory responses secreting heavy amounts of pro-
inflammatory mediators (including TNF-α, IL-1, IL-6, IL-8, nitric oxide and ROS generation), killing 
intracellular pathogens and driving T-helper (Th)-1 responses.  M2 macrophages promote 
contrasting anti-inflammatory/pro-resolution responses producing cytokines such as TGF-β, IL-10 
and vascular endothelial growth factor (VEGF), contain enzymes such as arginase (Arg-1) and 
are involved in the promotion of Th-2 responses and the killing of extracellular pathogens (111, 
114, 208).  These two different activated states are extensively distinguished throughout the 
literature by murine markers such as inducible nitric oxide synthase (iNOS), C-X-C motif 
chemokine 10 (CXCL10) for M1 macrophages and Ym1, Fizz1, Arg-1, Retnla and mannose 
receptor (CD206) associated with M2 phenotype (210).  It is becoming more appreciated that 
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there are specific subsets of M2 macrophages such as 2A, 2B and 2C which acquire different 
functional immunological properties that are microenvironment dependent (207).  It is now 
becoming more apparent that macrophages have a great deal of plasticity regarding their 
phenotype and have the capacity to switch from one activated state to another (260).   
Various subsets of macrophages reside locally within the heart, termed cardiac macrophages.  
These cells are involved in coordinating cardiac inflammation along with antigen sampling and 
wound repair (85, 257).  Dendritic cells are specialised antigen-presenting cells which link the 
innate and adaptive immune response.  They patrol both the blood and peripheral tissue where 
they process antigens through phagocytosis and present them to T-cells in lymphoid organs 
along with supplying cytokines that facilitate T-cell activation and differentiation (20, 21).  
Monocytes/macrophages and dendritic cells are implicated in many cardiovascular disorders and 
are well documented as playing a role in atherosclerosis and myocardial infarction (147, 318).   
Cells of the adaptive immune system have also been shown to be implicated in chronic 
inflammatory conditions such as heart failure.  T cells are the principal cells involved in adaptive 
immunity and arise from common lymphoid progenitor cells where they are defined into either 
CD4+ helper-T cells or CD8+ cytotoxic-T cells on the basis of their co-receptor (CD4 or CD8) 
which facilitates the binding of T cell antigen receptors to the antigen-bound major 
histocompatibility complex molecules (218).  Naïve CD4+ T-cells undergo proliferation and 
differentiation into lineage-specific effector cells such as Th-1 cells, Th-2 cells, Th-17 cells, 
regulatory T (Treg) cells and follicular helper T (Tfh) cells once activated by antigen presenting 
cells (391, 392).  Lineage-specific differentiation of T-cells depends on numerous factors 
including cytokine milieu, type of antigen presenting cell, concentration of antigen and type of co-
stimulatory molecules which activate lineage-defining master regulators that govern T-cell specific 
cellular phenotypes (135, 391).  CD4+ T-cells have previously been shown in animal models to 
contribute to cardiac remodeling and accelerating disease progression to heart failure (23, 184, 
240).  In patients, the percentage of CD4+ T cells in blood has been shown to correlate with LV 
dysfunction (104).  Interestingly, specific subsets of CD4+ T-cells can also be altered in chronic 
heart failure.  A study by Tang et al., found that patients with chronic heart failure had a significant 
reduction in the number and functional capacity of circulating Treg cells (which are governed by 
expression of the master regulator FoxP3) compared to healthy controls, with a correlation 
between Treg cell dysfunction and disease severity (322). 
The ability of immune cells to respond to various injurious and infectious stimuli is critical for 
homeostasis.  While it is well known that immunological memory is a trait of the adaptive immune 
system, it is becoming increasingly evident that there is the presence of immunological memory 
within innate immune cells, allowing for these cells to respond appropriately to certain stimuli 
(239).  Two examples of this innate immune memory are trained immunity and immunotolerance 
(such as endotoxin clearance) (8).  Trained immunity refers to when innate immune cells are 
primed by an initial challenge, allowing for an enhanced immunological response when they 
experience a secondary challenge.  After initial exposure of fungal wall products (such as β-
glucan), monocytes can mount an enhanced pro-inflammatory response by augmenting cytokine 
secretion upon second exposure (267).  Immunotolerance involves the suppression of innate 
immune cells where they enter a refractory functional state and do not respond upon re-
stimulation, as is the case with pre-stimulating monocytes with lipopolysaccharide (LPS) (217).   
Cellular differentiation into the effector cells of the immune system including both the innate and 
adaptive systems is accompanied by changes in gene expression.  Studies are now highlighting 
the role of epigenetic modifications as being important mechanisms involved in regulating gene 
expression for cellular differentiation, governing cellular phenotype and controlling cellular and 
immunological responses within the tissue microenvironment.  Alterations in these cellular 
processes could result in acquisition of a dysfunctional cellular phenotype which is followed by 
the promotion of improper cardiac wound healing.  
DNA Methylation in Immune Cells 
The implication of DNA methylation in dictating immune cell phenotype and cellular function is 
becoming increasingly apparent (Table 12).  It is involved throughout the various cellular stages 
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of haematopoiesis including the transition from haematopoietic stem cells (HSCs) to the various 
progenitor stages (multipotent progenitors (MPPs), common myeloid (CMP)/lymphoid progenitors 
(CLP), granulocyte-macrophage progenitors (GMPs)) and finally differentiation into effector cells 
of the immune system (monocytes, macrophages, granulocytes, T cells, natural killer (NK) cells 
and B cells) (8, 154).  Mice with reduced DNMT1 activity can only produce progenitors for the 
myeloerythroid lineage and are unable to generate lymphoid progenitor cells (39).  The function of 
de novo methylation by DNMT3 enzymes is also important because loss of both DNMT3A and 
DNMT3B function in HSCs results in impaired cellular differentiation and enhanced capacity for 
cellular self-renewal (52).  TET2 is also a critical regulator of self-renewal and differentiation of 
hematopoietic stem cells as deficiency of TET2 resulted in delayed HSC differentiation and 
skewed the development to monocyte/macrophage lineage (172).   
DNA methylation is becoming established as an important regulator of neutrophil differentiation, 
identity and function. Differential methylation analysis of human leukocytes revealed unique 
methylation signatures between cell subsets derived from either myeloid or lymphoid lineage. 
Neutrophils were found to have extensive hypomethylation compared to CD8+ T cells (153, 396). 
Furthermore, dynamic changes in DNA methylation are essential during stages of neutrophil 
differentiation and maturation. Ronnerblad and colleagues found reduced CpG methylation 
mirrored increased gene expression of both transcription factors (PU.1 and GFI1) and granule 
proteins (myeloperoxidase, elastase, and proteinase 3) in promyelocyte/myelocytes (granulocyte 
precursor cell) (276). Paradoxically, at the gene loci, mature neutrophils display a similar degree 
of hypomethylation at the same gene loci but their expression is markedly reduced (356). One 
proposed mechanism for this reduced gene expression in healthy mature neutrophils is by Runt-
related transcription factor 3 (RUNX3) (65). Aberrant neutrophil expression of myeloperoxidase 
and proteinase 3 has been demonstrated in neutrophils of patients with anti-neutrophil 
cytoplasmic autoantibody (ANCA) vasculitis (65). Interestingly, neutrophils from patients with 
ANCA vasculitis have a reduced expression of RUNX3 associated with increased DNA 
methylation at the RUNX3 promoter (65). This data highlights the role of DNA methylation in 
regulating inflammatory neutrophil function and is potentially relevant in the setting of cardiac 
injury. Regulation of CD4 and CD8 expression is critical for T cell identity.  T cells undergo 
multiple rounds of cell division after activation and therefore it is crucial that expression is finely 
tuned through heritable cellular processes to dictate the correct phenotype.  Sellars et al., 
reported that methylation of the CD4 locus by DNMTs is required to maintain CD4 silencing in 
cytotoxic CD8+ T cells and that stable expression of CD4 in CD4+ T cells is dependent on the 
cis-acting enhancer E4P-directed active DNA-demethylation (293).  Differentiation of CD4+ into 
subset-specific T-cells is also linked to DNA methylation including Th1 (289, 359), Th2 (155), 
Th17 (233, 375) and Treg cells (288, 399) as methylation is an underlying mechanism that 
facilitates the control of subset-specific T-cell gene expression.  Treg cells have essential 
immunosuppressive functions and their absence due to mutations of the FoxP3 gene is known to 
result in the development of systemic autoimmunity (395).  Thymically-derived Tregs are known 
as natural Tregs (nTreg) whereas Treg cells that arise from naïve CD4+ cells in the periphery in 
response to self or non-self-antigens and are dependent on TGFβ are known as induced-Treg 
cells (iTreg).  DNA methylation has been demonstrated as a potential factor for distinguishing 
these two subsets of Treg cells through modulation of FoxP3 (94).  Upstream of the FoxP3 
promoter lies a conserved CpG-rich region denoted as a Treg-specific demethylated region (167).  
This region is demethylated in nTreg cells with stable FoxP3 expression whereas in iTreg cells 
there is residual methylation in this region, resulting in less stability in its expression (135, 143).  
Furthermore, it is becoming clearer that DNA methylation may also play a role in the memory of T 
cells with differential gene methylation apparent between naïve and memory CD4+ T cells, 
enabling the memory cells to be primed and rapidly respond upon activation compared to naïve 
cells (175).DNA demethylation seems to be a major modification involved in the transition of 
monocytes into either macrophages or dendritic cells (170, 389).  Demethylation occurring in the 
differentiation of monocytes to macrophages has been shown to occur within the first twelve 
hours of stimulation with recombinant human monocyte colony-stimulating factor (M-CSF) (339).  
The involvement of TET2 in demethylation was demonstrated by use of the competitive 
dioxygenase inhibitor 2α-hydroxyglutarate (2-HG), which was associated with increased 
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methylation levels, preventing in vitro morphological changes (cellular protrusions) and 
adherence (339).  The authors demonstrated, using high throughput sequencing, that DNA 
demethylation occurs in distant enhancer regions in genes involved in signalling pathways which 
regulate the actin cytoskeleton and phagocytosis upon differentiation of monocytes to 
macrophages (339).  On the other hand, ex vivo differentiation of dendritic cells from monocytes 
was associated with 1,608 different methylation points (1367 of these demethylated), with only 
6% of these points located within CpG islands and the rest occurring at non-CpGI and 
transcription factor binding sites.  These changes in methylation throughout the genome were 
associated with alterations in expression of DNMT enzymes (DNMT1 and DNMT3A) and TET2 
(389).  Demethylation of CpGs in the promoter region of CD209, a dendritic cell specific marker, 
was shown to occur during the transition from monocyte to dendritic cells (41).  Vento-Tormo and 
colleagues have shown that differentiation of monocytes to dendritic cells through IL-4 stimulation 
results in activation of JAK3-STAT6 pathway, and promotes specific demethylation and 
subsequent activation of a subset of dendritic cell genes along with repression of macrophage 
specific genes (334).  Interestingly, a recent study by Pacis et al, has demonstrated that 
monocyte-derived dendritic cells undergo dynamic changes in DNA methylation at distal 
enhancer elements when infected with mycobacterium tuberculosis (251).  Regions that are 
hypomethylated were enriched near genes known to play a key role in the regulation of immune 
processes and were associated with genes differentially expressed in response to infection, 
implicating the role of DNA methylation in dendritic cell function (251).   
As DNA methylation plays an important role in regulating macrophage phenotype and function, 
alterations in the methylating machinery as a result of pathological conditions that contribute to 
heart failure development may result in an abnormal cellular behaviour.  Indeed, DNMT3B 
expression has previously been shown to be significantly elevated in macrophages isolated from 
adipose tissue of ob/ob obese mice compared with those isolated from lean controls (379).  In 
vitro knockdown of DNMT3B in Raw264.7 cells resulted in polarisation towards the M2 phenotype 
with expression of M2 markers (Arg1, mannose receptor C type 1, and macrophage galactose-
type c-type lectin) and profoundly reduced LPS- and stearate-induced inflammatory gene 
expression (TNF-α, IL-1β and iNOS) (379).  DNMT3B repression-induced M2 polarisation seems 
to be related to the methylation status of the CpG rich 5’ untranslated region of the PPARγ1 gene.  
Pyrosequencing analysis carried out by Yang et al, revealed that stimulation of macrophages with 
stearate increased DNA methylation at PPARγ1, which was significantly decreased by DNMT3b 
knockdown (379).   
Recent studies have also demonstrated the importance of the maintenance methylating enzyme 
DNMT1 in regulating macrophage phenotype and inflammation in various disease settings 
including obesity and atherosclerosis (345, 381).  Wang et al., demonstrated that macrophages 
isolated from the adipose tissue of ob/ob mice had a higher expression of DNMT1 and M1 
proinflammatory markers compared to lean controls (345).  They also found that mice with a 
myeloid-specific deletion of DNMT1 fed a high fat diet exhibited an increased presence of M2 
macrophages in the adipose tissue along with a reduction in basal and LPS-stimulated IL-6 and 
TNF-α expression from macrophages isolated from both adipose tissue and bone marrow (345).  
DNMT1 involvement in inflammatory cytokine release from macrophages has also been 
demonstrated in atherosclerosis (381).  Macrophages from transgenic mice with macrophage-
specific over-expression of DNMT1 were found to have increased circulating plasma levels of 
TNF-α, IL-6 and IL-1β which promoted atherosclerosis development (381).  For both these 
studies, the role of DNMT1-mediated macrophage phenotype and inflammation seems to be 
driven by increased methylation of the PPARγ proximal promoter, especially in response to pro-
inflammatory cytokines and saturated fatty acids (345, 381).  Decreased PPARy gene expression 
was found to be mirrored with an increased expression of DNMT1 and pro-inflammatory 
cytokines in monocytes isolated from patients with atherosclerosis (381).  Other potential targets 
for DNMT1 enabling the promotion of macrophage inflammation include the SOCS1 gene 
promoter.  Hypermethylation of SOCS1 promoter during LPS activation of macrophages resulted 
in the prolonged secretion of TNF-α and IL-6 (60), two major cytokines which correlate with 
disease severity in heart failure.   
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Two common comorbidities associated with the development of heart failure are hyperglycaemia 
in diabetes and hyperlipidemia in obesity.  Babu et al., carried out genome-wide DNA methylation 
sequencing to investigate alterations in DNA methylation in the proximal promoter regions of 
tissue macrophages isolated from hyperglycaemic and hyperlipidemic mouse models of hindlimb 
ischemia (15).  They identified 198 genes in the hyperlipidemia model and 272 genes in the 
hyperglycaemic model which showed proximal promoter hypomethylation.  Hypermethylation of 
proximal promoters was found in 102 genes in the hyperlipidemia model and in 136 genes in the 
model of hyperglycaemia (15).  Collectively this shows altered proximal promoter methylation in 
macrophages found in models of metabolic dysfunction.  Promoter methylation was shown to 
influence expression of macrophage subset-specific genes with hypermethylation and repression 
of M2 genes (Plxnd1, Nrp1, Cdk18 and Fes) and hypomethylation of M1 genes (Cfb, Serping1 
and Tnfsf15) in macrophages isolated form ischemic muscle.  Both methylation and expression 
analysis seemed to confirm the presence of a dominant pro-inflammatory macrophage phenotype 
within ischemic muscle with repression of the M2 phenotype in these models, confirmed by 
immunohistological assessment for TNF-α.  This persistent M1 phenotype was not observed 
within the control ischemic muscle (15).  Dysregulation of DNA methylation in the context of 
metabolic dysfunction could result in the abnormal persistence of the pro-inflammatory 
macrophage phenotype.  Interestingly, a long term follow up study of type 1 diabetic patients has 
recently demonstrated that persistent differential DNA methylation at key genomic loci was 
detected in both whole blood and monocytes is associated with diabetic complications (59).  
Considering that monocyte populations are altered in different types of heart failure (24, 112) and 
have the potential to differentiate into macrophages or dendritic cells in response to injury, these 
aberrant stable changes in DNA methylation in the setting of metabolic dysfunction may explain 
why comorbidities such as obesity and diabetes contribute to aberrant inflammatory responses 
and the development of cardiomyopathy. 
Pharmacological intervention of DNMT activity has been shown to modify both cellular phenotype 
and function.  Acquisition of FoxP3 expression, a marker of Treg cells, can be achieved in NK 
cells when stimulated by IL-2-induced STAT signalling but only in the presence of 5azadC, 
suggesting the reprogramming of cellular identity through DNMT inhibition (399).  5azadC can 
also induce transition of CD4+ Tcells into Treg cells ex vivo without the presence of TGFβ and 
has demonstrated beneficial effects in cardiac allograft survival upon adoptive transfer of these 
transformed cells in combination with continuous 5azadC treatment (61).  Dendritic cells derived 
from monocytes and activated in vitro in the presence of 5aza were found to secrete lower levels 
of IL-10 and IL-27 cytokines (102).  With these changes seen in vitro, Frikeche and colleagues 
followed up to investigate if these changes in cytokine secretion by activated DCs could influence 
T cell responses in vivo in a small cohort of MDS patients who received 5aza treatment.  Patients 
who were treated with 5aza showed promotion of Th-17 response showing a significant reduction 
in IL-4−secreting CD4+ T cells but an increase in both IL-17A−secreting CD4+ T cells and IL-
21−producing CD4+ T cells (102), suggesting that inhibition of DNMT can influence expression of 
genes that are normally silenced, modulating cellular phenotype and identity.   
Interestingly, the precise role of Th17 cells in heart failure is unclear. Certain studies have 
demonstrated augmented levels of Th17 cells and their relevant cytokines to be associated with 
increased disease severity (191, 235), while others have failed to show any significant difference 
in heart failure patients (394). Disease association could be due to alterations in the balance 
between anti-inflammatory Treg cells, known to be reduced in HF, and Th17 cells. As a result, 
modulating T cell phenotype and function may have the potential to restore balance and prevent 
inappropriate inflammatory responses.  
DNMT inhibitors seem to demonstrate beneficial effects in animal models of cardiovascular 
disease.  In atherosclerosis, Ldlr-/- mice which were treated with 5azadC showed reduced 
atherosclerotic development independent of atherogenic factors including circulating plasma lipid 
and cholesterol levels and lipid content of the plaques (46).  Macrophage content was found to be 
decreased in plaques of 5azadC treated mice along with decreased inflammatory gene 
expression (TNF-α, IL-1β, IL-6 and iNOS) in macrophages isolated from Ldlr-/- treated mice.  The 
atheroprotective effect seen with 5azadC on macrophages was mirrored by reduced methylation 
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at the promoter region of LXRα and PPARγ with increased gene expression (46).  Similarly, 
5azadC was also found to have a beneficial effect in obesity through effects on PPARy 
expression.  Ob/ob mice treated with 5azadC were found to have an improvement in glucose 
levels and insulin sensitivity, associated with an increased presence of M2 macrophages in 
adipose tissue (345).  Macrophages isolated from the adipose tissue of ob/ob mice treated with 
5azadC were found to have an increased expression of PPARy compared to their saline treated 
littermates.  Reducing the inflammatory potential of macrophages with 5azadC has also been 
demonstrated by preventing SOCS1 hypermethylation (60).  Modulation of macrophage 
phenotype with 5aza in the context of myocardial infarction is associated with therapeutic benefit, 
reduced cardiac fibrosis and improvement in cardiac function (152, 168).  Treatment of rats with 
5aza was shown to reduced infiltration of macrophages into the infarcted area, with a more 
prominent M2 phenotype being present in the 5aza treated hearts compared to an M1 phenotype 
seen in control animals (168).  Modulation of macrophage phenotype in myocardial infarction by 
5aza has been recently associated with transcriptional activity of interferon regulatory factor-1 
(IRF1) (152).  5aza was shown to maintain levels of IRF1, a transcription regulator of iNOS, in 
macrophages by preventing proteasomal degradation through sumoylation and therefore 
repressing the pro-inflammatory M1 phenotype (152). 
It is critical that we must also acknowledge the limitations of in vitro findings that are based on 
commercial versus primary cell lines with regard to results from pharmacological DNMT inhibition.  
It was recently highlighted by Wang and colleagues using bisulfite conversion followed by 
pyrosequencing that differential basal methylation exists at the PPARy promoter between the 
commercial Raw 264.7 cell line (33-36% methylation rate) and primary isolated BMDMs (3% 
methylation rate) (345).  While methylation of the PPARy gene was found to increase dramatically 
in BMDMs in response to inflammatory stimuli (345), the high basal methylation rate found in 
commercial cell lines such as the Raw264.7 may impact the in vitro effects seen with DNMT 
inhibition.  As a result, this difference in methylation status between commercial versus primary 
cells should definitely be considered for the selection and design of future in vitro inflammatory 
cell experimentation looking at the effect of DNA methylation.   
 
Histone Acetylation in Immune Cells 
Understanding the molecular mechanisms that modulate immune cell phenotype and 
inflammatory gene expression is hoped to provide novel therapeutic avenues for inflammatory 
conditions.  The contribution of acetylation and deacetylation of histone proteins to inflammation 
is starting to become apparent in various inflammatory conditions including rheumatoid arthritis 
(64), inflammatory lung diseases (25) and multiple sclerosis (91).  Therefore, it is no wonder that 
acetylation and deacetylation contribute to inflammation in cardiovascular diseases (347).  
Numerous preclinical models of heart failure have demonstrated improvements in cardiac 
function after therapeutic manipulation of histone acetylation and deacetylation while also 
displaying beneficial effects on reducing inflammation (47, 148, 248, 361).  While the exact 
mechanism behind the therapeutic reduction of inflammation in these models remains unknown, 
one possible mechanism could be through regulation of immune cell phenotype and cellular 
function. 
Polarisation into specific macrophage phenotypes has been demonstrated to be influenced by 
acetylation and deacetylation (Table 13).  It has been shown that histone modifications can 
participate in controlling macrophage function at both promoter and enhancer regions so that they 
are primed and ready to respond to various stimulating factors in their microenvironment (108).  
For example, IFN-γ has been shown to prime macrophages that were purified from PBMCs by 
recruiting transcription factors (STAT1 and IRF-1) and HATS (p300 and CBP), increasing 
acetylation at promoter and enhancer regions of inflammatory cytokines TNF, IL6 and IL12B to 
augment their expression when exposed to LPS (265). 
As previously mentioned by Kapellos and Iqbal, only a limited number of studies have 
demonstrated the involvement of HATs in regulating M1 or M2 associated genes (161).  A study 
by Feng et al., highlighted the role of p300 in binding to the promoter regions of IFNA, TNF-α and 
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IL-6 with IRF5 in response to viral infection (92).  The majority of the studies have looked at the 
role of HDACs on regulating macrophage polarisation.  HDAC3 has been previously portrayed in 
the literature as a key regulator involved in macrophage polarisation and inflammatory cell 
function (58, 234).  Deletion of HDAC3 in macrophages, under the control of the myeloid-specific 
Lysozyme M promoter, facilitated a gene expression profile similar to an M2 phenotype (234).  
Treatment of HDAC3-deficient macrophages with IL-4 or IL-13 markedly potentiated the induction 
of genes associated with M2 activation (including Arg1, Clec7a, Ym1, and Retnla) (234).  It is now 
appreciated that the ETS family of transcription factors (including PU.1), which have long been 
known to participate in macrophage development (292), have the ability to interact with and 
recruit chromatin remodeling enzymes and other transcription factors in response to stimuli in 
order to fine tune macrophage gene expression (108, 130).  HDAC3 was found to bind to PU.1-
guided enhancer regions and through deacetylation, functions to suppress expression of IL-4 
target genes and therefore sequestering M2 cellular phenotype (234).  The influence of HDAC3 in 
promoting pro-inflammatory macrophage phenotype was confirmed by Chen and colleagues, 
where they found that HDAC3 is required for inflammatory gene expression in response to LPS 
through IFN-β production as this allows for the maintenance of STAT1 expression (58).  In the 
context of atherosclerosis and inflammation, HDAC3 was previously found to be overexpressed in 
human atherosclerotic lesions whereby immunohistochemical analysis revealed co-localization of 
HDAC3 to CD68+ cells in atherosclerotic plaques (136).  Interestingly, macrophage-specific 
deletion of HDAC3 was found to induce an athero-protective macrophage phenotype improving 
plaque stability (136).  Other studies have also demonstrated modulation of macrophages 
through pharmacological inhibition of HDAC3, where HDACi reduced macrophage apoptosis and 
expression of IL-6 and NO in response to pro-atherogenic molecules (oxidized Low-density 
lipoprotein (LDL) and 7-ketocholesterol) (136).   
Other HDACs have also been involved in regulating macrophage inflammatory response 
including HDAC5, 7 and 9.  Previous in vitro analysis has demonstrated the regulatory role of 
HDAC5 with regard to cytokine production in both human and murine monocyte/macrophage cell 
lines (259).  Over expression of HDAC5 resulted in increased NF-B activation along with 
augmented levels of both pro-inflammatory cytokines (TNF-α and MCP-1) and anti-inflammatory 
cytokines (IL-10) (259).  Significant reduction of TNF-α and MCP-1 expression was seen after 
knockdown of HDAC5, which was found to be independent of NF-B activation (259).  HDAC6 is 
also implicated in driving a pro-inflammatory macrophage phenotype as suppression of HDAC6 
levels and its activity significantly impaired LPS-induced macrophage activation (371).  HDAC7 
levels have previously been shown to be elevated in thioglycolate-elicited peritoneal 
macrophages where an alternatively-spliced isoform of HDAC7 (lacking the first 22 amino acids 
at the N-terminus) is involved in promoting the expression of a subset of proinflammatory genes 
in macrophages through interaction with HIF-1α (296).  HDAC9 expression was found to be 
increased in macrophages differentiated from bone marrow-derived cells and THP-1 monocytes 
(45).  HDAC9 deficiency in macrophages resulted in decreased LPS-induced inflammatory gene 
expression, improved cholesterol efflux and polarisation toward the M2 phenotype associated 
with increased histone acetylation at the promoters of ABCA1, ABCG1, and PPAR-γ (45).  The 
role of HDACs, including class III/sirtuins, in promoting macrophage phenotype and function has 
been reviewed previously (71, 161). 
Dynamic changes in histone acetylation can contribute to the immunological response of innate 
immune cells.  A study by Saeed et al., has demonstrated dynamic changes in histone acetylation 
upon differentiation of monocytes to macrophages and how these changes can participate in 
specific innate immune responses i.e. trained immunity (with β-glucan stimulation) versus 
endotoxin tolerance (with LPS stimulation) (281).  The authors identified four epigenetically 
marked clusters that reflect general transcriptional regulatory regions and are differentially 
modulated in trained and tolerant immune responses.  They found that H3K27 acetylation levels 
changed at thousands of promoters and distal regions, with acetylation levels correlating well with 
changes in gene expression (281).    
HDACs are crucial for normal immune cell development and function.  HSCs that are deficient in 
HDAC3 have impaired capacity for self-renewal due to defects in DNA replication (311).  
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Differentiation of HSCs to lymphoid progenitor cells is also impaired in HDAC3-deficient HSCs 
resulting in a dramatic loss of B and T cells (311).  HDAC3 is also essential for the correct and 
efficient maturation and positive selection of CD4+ and CD8+T cells (310).  Now while 
deacetylation is essential for normal cell development during the progenitor stage, its role in cells 
which have undergone subsequent differentiation and have less plasticity could be relevant in 
promoting aberrant phenotypes in cells of the adaptive immune system.  Pharmacological 
inhibition of HDAC activity has been highlighted to have numerous effects on dendritic cell 
differentiation (56, 238, 312) and function (103) including attenuated expression of co-stimulatory 
molecules (38, 193, 271), cytokine secretion (188, 238, 305) and modulating antigen uptake and 
antigen-specific immune responses (38, 193, 271, 305).  One of the proposed mechanisms by 
which HDACi demonstrate their anti-inflammatory potential is through generation of Treg cells 
(326).  Indeed, in the context of pathological cardiac remodeling, adoptive transfer of Treg cells 
was shown to blunt Angiotensin-II–induced cardiac hypertrophy and fibrosis, independent of any 
effect on blood pressure (181).  It is well understood that both HATs and HDAC are involved in 
promoting and maintaining the functional Treg phenotype (122).  Acetylation by HATs including 
p300 and TIP60 has been shown to maintain Treg viability and cellular phenotype through 
modulation of FoxP3 by preventing its degradation and increasing its ability to bind DNA, 
promoting transcriptional activity (197, 333).  Deacetylation by HDAC enzymes has also been 
implicated in negatively regulating Treg identity and function (6), and has been demonstrated by 
genetic and pharmacological targeting of HDAC3 (342), HDAC6 (28, 76, 197), HDAC9 (28, 77, 
326), and Sirt1 (28) (Table 14).   
New efforts are underway to develop novel HDAC inhibitors that are specifically designed to 
target cells of monocytic lineage in order to reduce systemic exposure.  Tefinostat (CHR-2845) is 
a cell-permeant ester that gets cleaved by the human carboxylesterase-1, hCE1 (which is only 
present in hepatocytes and cells of monocytic lineage) to an acid which accumulates within these 
cells as it is impermeable due to its charge (383).  Tefinostat has demonstrated early signs of 
efficacy and was found to be well tolerated with an absence of significant toxicity in a phase I 
clinical trial in patients with advanced haematological malignancies (NCT00820508) (249).  This 
drug is currently in a single-arm Phase 2 study of monotherapy in chronic myelomonocytic 
leukaemia (MONOCLE) and in a Phase I/II dose escalation trial for cancer associated 
inflammation in hepatocellular carcinoma (NCT02759601).  While more information will be 
needed to investigate how specific and effective these new class of myeloid-specific HDAC 
inhibitors are, the potential to selectively target monocytic cells could have translational potential 
in inflammatory conditions such as heart failure. 
 
Histone Methylation in Immune Cells 
Evidence suggests that modulation of immune cell phenotype and function is attributed to both 
methylation and demethylation of histone proteins.  Like other epigenetic processes mentioned, 
addition and removal of methylated histone marks through transcription factor recruitment is 
essential for regulating cellular differentiation of immune cells  including HSCs (70), progenitor 
cells (70), dendritic cells (355) and CD4+ T-cells (127, 358).  Further highlighting the important 
role of histone methylation machinery in maintaining normal leukocyte biology is that alterations in 
these enzymes are associated with human haematological malignancies (2, 58, 150).   
Polarisation of macrophages into a particular activated state can be driven by modulation of 
histone methylation.  Studies have demonstrated the importance of histone demethylase 
enzymes in characterizing the M1 and M2 macrophage phenotype.  One histone demethylase 
that has been identified as a prominent regulator of the M2 phenotype is the JMJD3 H3K27 
demethylase, which catalyzes demethylation of H3K27me3 to H3K27me1.  M2 marker genes 
(Arg1, Ym1 and Rentla) were shown to be increased through IL-4/STAT6-upregulation of JMJD3 
and subsequent reduction of H3K27me3 methylation at their gene promoters (146).  Involvement 
of JMJD3 demethylase was further supported using the Schistosoma mansoni egg challenged in 
vivo model of M2 activation (146).  Other studies have also demonstrated the regulation of the M2 
phenotype by JMJD3 in response to stimuli such as M-CSF and chitin (286).  While Satoh et al., 
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did not find differences in H3K27 methylation at the M2 gene promoters (Arg1, Ym1 and Rentla) 
in JMJD3 deficient M-CSF stimulated bone marrow-derived macrophages (BMDMs), they did 
demonstrate that IL-4 could still up-regulate M2 associated genes in these cells independently of 
JMJD3 (286).  Up-regulation of M2 markers (Arg1, Ym1, Fizz1 and CD206) in response to chitin 
and M-CSF was found to be dependent on JMJD3 demethylation of H3K27 at the Irf4 promoter, 
enhancing its transcription and M2 marker gene expression (286).  Alternatively, JMJD3 has been 
implicated in promoting the expression of pro-inflammatory mediators (IL-23p19, TREM-1 and G-
CSF) in BMDMs through increasing H3K27 promoter demethylation in response to serum amyloid 
A (373).  Demonstrating that regulation of macrophage phenotype by histone demethylase 
enzymes is ultimately dependent on the context of the microenvironment, as is the case for 
certain histone demethylases that have been shown to be induced by HIF-1α in hypoxia (376).  
More recently it has been highlighted that alterations in histone methylation in bone marrow 
progenitor cells may influence the inflammatory macrophage phenotype and impair wound 
healing in T2DM (105).  Gallagher and colleagues have demonstrated increased levels of JMJD3 
and expression of proinflammatory cytokines such as IL-12 in bone marrow-derived progenitor 
cells and macrophages in both human and preclinical models of T2DM (105).  Increased 
expression of IL-12 was mirrored by decreased H3K27me3 at the IL-12 gene promoter (105).  
Consequently, inhibition of JMJD3 activity using the selective H3K27 demethylase inhibitor, GSK-
J4, resulted in a dose dependent decrease in proinflammatory gene expression in response to 
LPS (IL-12, IL-1Β and IL-6) (105).  Elevated levels of JMJD3 have also been linked to reduced  
H3K27me3 methylation and increased expression of myeloperoxidase and proteinase 3 in 
patients with ANCA vasculitis (65).   
Methyltransferases have also been implemented in the regulation of macrophage polarisation and 
function.  In response to acquiring the M1 phenotype, there is upregulation in the levels and 
activity of H3K4-specific methyltransferase KMT2A, which was found to increase H3K4me3 in the 
promoter region of CXCL10 (169).  Pre-treatment of macrophages with MI-2-2, a small molecule 
inhibitor preventing the interaction between KMT2A and its cofactor menin, resulted in a reduction 
in the number of CXCL10 positive cells (169).  Other lysine methyltransferases such as KMT2B 
have also been previously linked to governing macrophage responses to microbial stimuli.  
Deficiency in this methyltransferase prevents H3K4me3 methylation at the transcription start site 
of the Pigp gene and results in an impaired macrophage response to LPS (12).  The role of 
different histone methylating and demethylating enzymes in contributing to macrophage 
phenotype and function are reviewed further elsewhere (161). 
As highlighted previously, innate immunological memory is achieved by cellular processes that 
modulate gene expression, with methylation of histone proteins being a key regulator.  
Demonstration of histone methylation in trained innate immunity was described by Quinten and 
colleagues whereby they primed monocytes with a low dose of β-glucans from C. albicans and 
found an enhanced production of inflammatory cytokines (TNF-α and IL-6) upon second 
stimulation with various infections stimuli (267).  They found that innate immunological training 
after β-glucan treatment was attributed to global increases in H3K4me3 marks, with an increased 
presence at the promoter regions of proinflammatory genes such as TNF-α, IL-6, and IL-18 that 
strongly correlated with their increased expression (267).  Interestingly the authors found 
increased gene expression of other histone methyltransferases after innate immune training such 
as SETD7, which has been previously implicated in promoting pro-inflammatory gene expression 
in monocytes (192).  The work carried out by Foster and colleagues demonstrated the role of 
histone methylation in modulating different classes of TLR-induced genes to achieve 
immunotolerance in macrophages in response to LPS (96).  These two classes of genes include 
tolerant (such as pro-inflammatory cytokines e.g.  IL-6) and non-tolerant genes (such as formyl 
peptide receptor 1) with their regulation being attributed to the transcriptionally active H3K4me3 
mark at their promoters (96).  When tolerant macrophages were stimulated with LPS, H3K4me3 
would be selectively lost in tolerant genes but maintained on non-tolerant genes.  This was 
confirmed using an inhibitor of H3K4 demethylase LSD1, which prevented IL-6 silencing in 
tolerant macrophages (96).  The maintenance of H3K4me1 marks at latent enhancer regions of 
the genome, deposited in response to stimuli such as LPS, have also been proposed to 
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contribute to innate immunological memory and macrophage function, even after the stimulus has 
been removed (250).   
Histone H3K9 methylation has been shown to play a role in the regulation of dendritic cell 
inflammatory responses.  Upon LPS treatment, demethylation of H3K9 and recruitment of RNA 
polymerase II was associated with activation of pro-inflammatory gene expression in dendritic 
cells (280).  Recruitment of transcriptional machinery was shown to correlate with H3K9 
demethylation rather than acetylation of H3 and H4 proteins (280).  Furthermore, dendritic cells 
show significantly lower levels of H3K9me2 and H3K4me3 at both IFN and IFN-inducible genes 
suggesting that these cells are epigenetically programmed to respond to inflammation (89).  Of 
note, Prakash and colleagues have demonstrated impairment of IFN secretion by monocyte-
derived dendritic cells from aged individuals in response to the influenza virus.  This age-
associated decline in dendritic cell function was associated with increased H3K9me3 in non-
stimulated aged-DCs and decreased H3K4me3 marks upon viral stimulation in the promoter 
regions of IFN and IL-29 genes (263). 
The microenvironment can influence naïve CD4+T-helper cell differentiation into various T-helper 
cell responses including Th1 and Th2.  Cytokines can activate various signalling pathways 
including STAT proteins, allowing for emergence of specific T-helper cell subsets (189).  
Regarding IL18rap gene expression in T-helper cells, STAT4 (activated by IL-12) promotes 
permissive marks such as H3K4me3 in Th1 cells, promoting IL18rap gene transcription, whereas 
STAT6 (activated by IL-4) is critical at establishing repressive H3K27me3 marks at the same 
locus of the IL18rap gene in Th2 cells (354).  This demonstrates the ability of STAT proteins to 
modulate histone methylation at the same genomic loci creating opposing function allowing gene 
regulation for T-helper cell differentiation (354).  Regulation of FoxP3 expression in Treg cells has 
also been attributed to histone methylation.  It was found that Treg cells lose their FoxP3 
expression (FoxP3-losing cells) during in vitro expansion (noticeable at 2 weeks) with down-
regulation of SOCS2, a protein involved in maintaining FoxP3 stability (171), mirrored with 
increased expression of Th2-lineage genes such as GATA3, GFI1, IL-13 (126).  In FoxP3-losing 
cells, H3K4me3 marks (associated with active transcription) were absent at the FoxP3 promoter 
but were found at considerably higher levels in IL-4 and IL-5 genes, correlating with their 
increased expression.  Interestingly there was no difference in H3K4me3 levels in the GATA3 
gene between FoxP3+ cells and FoxP3-losing cells and the authors speculate that it could be due 
to a complex relationship between FOXP3 and GATA3 (278) and these permissive H3K4me3 
marks provide a prerequisite for GATA3 up-regulation in these cells for T-cell plasticity (126). 
Th17 differentiation has also been shown to be highly regulated by histone methylation. Jumonji- 
and AT-rich interaction domain (ARID)-domain-containing protein 2 (JARID2) is a DNA-binding 
protein that interacts with PcG2 to negatively regulate Th17 gene expression through H3K27 
methylation (87). miR-155 is highly expressed in Th17 cells and has been shown to negatively 
regulate expression of JARID2 (87), highlighting the complex nature of non-coding RNA 
influencing epigenetic regulation of histone methylation to facilitate Th17 differentiation. 
 
Problems Faced With Targeting Inflammation in Heart Failure 
With inflammation being a hallmark of cardiac injury, it was presumed that agents that target 
inflammatory mediators released by cells of the immune system may yield a beneficial form of 
therapy for the treatment of heart failure.  Previous approaches investigated include antagonizing 
the effects of inflammatory cytokines such as TNF.  Two strategies were employed for 
antagonizing the actions of TNF such as using soluble decoy receptors (Entanercept) and using 
chimeric monoclonal antibodies (Infliximab) to neutralize the effects of TNF.  These were 
investigated in large scale multi-centre clinical trials; The Randomized Etanercept North American 
Strategy to Study Antagonism of Cytokines (RENAISSANCE, n=900 patients) trial, Research into 
Etanercept Cytokine Antagonism in Ventricular Dysfunction (RECOVER, n=900 patients) trial and 
Randomized Etanercept Worldwide Evaluation (RENEWAL, n=1500 patients) investigated the 
therapeutic potential of Entanercept and the phase II trial Anti-TNFα Therapy Against CHF 
(ATTACH, n=150 patients) examined the use of infliximab in moderate to advanced heart failure 
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(202, 203)       While these agents are used clinically for the treatment of inflammatory conditions 
such as rheumatoid arthritis, these trials failed to demonstrate any therapeutic benefit in heart 
failure patients.  The trials also revealed that anti-TNF therapy adversely affected the course of 
the disease with all three trials demonstrating increased all-cause mortality and hospitalizations 
with the anti-TNF treatment groups (18, 67, 204).  The exact reasons for the adverse outcome 
of anti-TNF therapy seen in heart failure remain unclear; however one plausible mechanism for 
the detrimental outcome that has been alluded to is that anti-TNF therapy (e.g.  Infliximab) binds 
to TNF expressed on the sarcolemma of failing cardiac myocytes causing cellular apoptosis 
through complement fixation, promoting disease progression and cardiac failure (139, 203).  
Perhaps the focus should be on targeting the inflammatory cells themselves rather than targeting 
the molecules they produce, either by inhibiting their recruitment to the heart or by modulating 
their inflammatory potential in the heart directly.  While targeting local inflammation directly in the 
injured heart is an extremely challenging obstacle, targeting the activation, mobilization and 
recruitment of pro-inflammatory cells to the heart might enable a more promising therapeutic 
window.  Recently, in ischemic cardiomyopathy, the spleen has been implicated as a source of 
inflammatory cells including monocytes, macrophages, dendritic cells (pDCs and cDCs) and 
CD4+ T cells, which possess an activated pro-inflammatory state that is maintained upon 
adoptive transfer and can induce pathological cardiac changes in naïve animals (23, 147).  While 
the reticuloendothelial role and microanatomy of the spleen has been a major challenge for 
effective delivery and pharmacokinetics of micro and nanoparticle based compounds (50), this 
could be utilized as an advantage to deliver targeted therapy specifically to specific pro-
inflammatory cell populations before they mobilize to the heart.  Indeed compounds already in 
clinical use have been shown to readily accumulate in cells of the spleen such as Clofazimine, an 
antibiotic and anti-inflammatory drug used for the treatment of leprosy and skin inflammation that 
has been shown to be readily taken up and stored by macrophages in the spleen (17).  Delivering 
anti-retroviral treatment specifically to splenic macrophages has also become an attractive target 
for the treatment of HIV (270).  While the specific antigenic activation that promotes the 
pathological change in splenocytes in ischemic heart failure is unknown, epigenetic mechanisms 
could be involved in retaining their pathological cellular memory.  This could therefore act as a 
novel therapeutic window to directly modulate inflammatory cell phenotype and function with 
epigenetic modifying therapies.   
 
Conclusion 
The cardiac response to injury involves a complex interplay of tissue resident cells such as 
endothelial cells, fibroblasts, cardiomyocytes, and immune cells, and infiltrating inflammatory and 
mesenchymal precursor cells.  Physiological adaptation to injury or stress requires the 
maintenance of tissue integrity, via appropriate ECM deposition, cardiomyocyte hypertrophy in 
order to maintain cardiac output, and adaptation of the vasculature in order to support myocyte 
function.  Physiological adaptation is followed by resolution of inflammation and myofibroblast 
function, remodeling of ECM to match the degree of strain in the myocardium, and stabilisation of 
new blood vessels.  In pathological settings either persistent injury, exaggerated inflammatory or 
fibrotic responses, inadequate angiogenic responses, or uncontrolled myocyte hypertrophy, or 
quite possibly a combination of a number of these events, leads to aberrant wound healing and 
cardiac dysfunction.  Physiological responses to injury are complex and clearly require carefully 
controlled changes in cellular phenotypes, in both resident and infiltrating cells, which are dictated 
by altered transcriptional profiles.  The persistence of activated inflammatory cells, activated 
myofibroblasts and hypertrophic cardiomyocytes during aberrant wound healing situations 
suggests the involvement of epigenetic mechanisms that lead to the survival of cells with stable 
phenotypic changes. 
The role of epigenetic changes in the pathogenesis of heart failure is increasingly apparent; 
however the majority of our knowledge has come from studies utilizing cardiac tissue from 
patients and animal models, which contains a mix of different cell types, or in vitro cell culture 
systems.  It is clear that epigenetic changes can occur in different cell types, at different rates, at 
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different sites and can have differential effects depending on the cellular context.  Ex vivo 
isolation of individual cell types from injured myocardial tissue, and subsequent analysis of 
epigenetic modifications, is greatly improving our understanding of disease-relevant alterations in 
chromatin structure and transcriptional activity.  The goal of this overview was to highlight the 
specific changes in DNA methylation, histone acetylation and methylation which independently 
contribute to an aberrant cellular phenotype, focusing specifically on cells that are involved in 
cardiac dysfunction such as cardiomyocytes, fibroblasts and immune cells.  It is becoming 
increasingly apparent that endothelial cells play an important role in the pathophysiology of heart 
failure. Both DNA methylation and histone modifications have been previously shown to modulate 
endothelial cell-specific genes (such as eNOS, Von Willebrand factor and CD31) (97, 302) and 
govern essential biological processes central to the wound healing response such as 
angiogenesis, inflammation and response to blood flow (212). While not covered as part of this 
review, the regulation of endothelial cell gene expression by DNA methylation and histone 
modifications has been reviewed elsewhere (97, 212, 372).   
Remarkable progress has been made in our understanding of the ability of DNA methylation and 
histone modification to promote altered cellular functional responses to injurious stimuli, even in 
post-mitotic cells.  It is also well known that these epigenetic processes interact with each other 
along with ATP-dependent chromatin remodeling complexes and non-coding RNAs (miRNAs and 
lncRNAs), forming a complex regulatory network to facilitate intense regulation of chromatin 
structure and gene expression.  The ability of epigenetic changes to be inherently reversible has 
always been an attractive concept for therapeutic intervention, yet there are currently no 
epigenetic-modifying therapies approved or under clinical investigation for the treatment of 
cardiovascular diseases.  Nevertheless, in the context of heart failure, this field remains at an 
exciting early stage with efforts currently being undertaken to develop more selective agents that 
target specific epigenetic processes in certain cell types involved in pathological events such as 
fibrosis and inflammation.  Further investigation into the exact involvement of these epigenetic 
mechanisms specifically in aberrant cardiac remodeling, combined with the development of cell-
targeted strategies could potentially lead to the translation of epigenetic modifying therapies for 
clinical benefit in heart failure. 
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Tables 
 
Table 1: Abbreviations  
 
2-HG 2α-hydroxyglutarate LncRNA Long non-coding RNAs 
5aza 5-azacytidine LPS Lipopolysaccharide 
5azadC 5-aza-2-deoxycytidine LV Left ventricle 
5hMeC 5-hydroxymethylcytosine MBD Methyl-CpG-binding domain protein 
5MeC 5-methylcytosine MCP-1 monocyte chemoattractant protein-1 
AMOTL2 Angiomotin-like protein 2 MDS Myelodysplastic Syndromes 
AngII Angiotensin-II MeCP Methyl-CpG-binding protein 
ANCA Anti-neutrophil cytoplasmic autoantibody MI Myocardial infarction 
Arg-1 Arginase-1 Mef2 Myocyte enhancer factor-2 
ARHGAP24 Rho GTPase activating protein 24 MIP Macrophage Inflammatory Protein 
BMDMs Bone marrow-derived macrophages miRNA Micro RNA 
BMP bone morphogeneic protein MMPs Matrix metalloproteinases 
BMPER BMP-endothelial cell precursor-derived 
regulator 
MPPs Multipotent progenitors 
Chaer Cardiac hypertrophy associated epigenetic 
reader 
Myl7 atrial myosin light chain 
ChIP Chromatin immunoprecipitation NK Natural Killer 
CLP Common Lyphoid Progenitor NT-
proBNP 
N-terminal pro b-type natriuretic peptide 
CMP Common Myeloid Progenitor nTreg natural T-regulatory cells 
CPGi CpG islands PBMC Peripheral blood mononuclear cell 
COX2 Cycloxygenase-2 PcG Polycomb group 
CpGs Cytosine-(phosphate)-Guanine dinucleotide PCM-1 Pericentriolar material-1 
CXCL C-X-C motif chemokine PCR2 Polycomb repressor 2 complex 
DNA Deoxyribonucleic acid PDGF Platelet derived growth factor 
DNMT DNA  methyltransferase  PECAM Platelet endothelial cell adhesion molecule 1 
DOT1L Disruptor of telomeric silencing 1-like PPAR Peroxisome proliferator activated receptor 
DZNep 3-Deazaneplanocin A 
PTIP 
PAX interacting with transcription-activation 
domain) protein 1 
ECM Extracellular Matrix PTMs Post Translational Modifications 
EMA European Medicines Agency RAAS Rennin-Angiotensin-Aldosterone System 
EMT Epithelial to mesenchymal transition RASAL1 RAS Protein Activator Like 1 
EndMT Endothelial to mesenchymal transition RASSF1A Ras association domain family 1 isoform A 
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EZH2 Enhancer of zeste homolog 2 ROS Reactive Oxygen Species 
FDA Food and Drug Administration SAHA Suberoylanilide hydroxamic acid 
FHL1 Four-and-a-half LIM domains protein 1 SAM S-adenosylmethionine 
GMPs Granulocyte-macrophage progenitors SHR Spontaneously Hypertensive Rat 
GNAT GCN4-related N-acetyltransferase SIRTs Sirtuins 
HATs Histone Acetyltransferases SNPs Single nucleotide polymorphisms 
HDACis Histone Deacetylase inhibitors STAT Signal transducer and activator of transcription 
HDACs Histone Decetyltransferases T2DM Type 2 Diabetes Mellitus 
HF Heart failure TAB-seq TET-assisted bisulfite sequencing 
HMT Histone methyltransferase TAC Transaortic Constriction 
HSCs Haematopoietic stem cells TET Ten-eleven translocation 
HStCs Hepatic stellate cells Tfh T-helper follicular cell 
IFN Interferon TGF Transforming Growth Factor 
IGF Insulin-like growth factor Th T-Helper 
IL Interleukin TIMPs tissue inhibitor of metalloproteinases 
iNOS Inducible nitric oxide synthase TNF  Tumour Necrosis Factor 
IRF1 Interferon regulatory factor-1 Tnni Troponin isoform 
iTreg Induced Treg cells Tnnt2 Troponin II 
JMJDs Jumonji C-domain containing demethylases Treg T-regulatory cell 
KLF4 Krüppel-like factor 4 TrxG Trithorax Group 
KMT Lysine methyltransferase TSA Trichostatin A 
KO Knockout VEGF Vascular Endothelial Growth Factor 
LDL Low-density lipoprotein WGBS Whole genome bisulfite sequencing 
LINE-1 Long interspersed nuclear element-1   
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Table 2: DNA Methylation Changes in Heart failure  
 
Changes in DNA methylation Heart failure (HF) 
status/Patient cohort 
Genes/elements influenced by 
changes 
Ref 
    
Global promoter hypomethylation & 
Intragenic hypermethylation 
 
End-stage HF 
(ischaemic and 
idiopathic) 
 
DUX4 (230) 
Hyper/hypomethylation of gene loci 
 
End-stage HF 
(ischaemic and 
idiopathic) 
 
PECAM, AMOTL2, ARHGAP24 (229) 
Hyper/hypomethylation of gene loci 
 
Dilated cardiomyopathy 
 
LY75 & ADORA2A (121) 
Global hypomethylation Ischemic heart 
disease/stroke 
 
LINE-1 (16) 
Global hypomethylation 
& 
Reduced DNMT1, DNMT3A and DNMT3B 
expression 
Tetralogy of Fallot LINE-1 (299) 
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Table3:  Histone Acetylation and Deacetylation in Clinical and Preclinical Models of Heart Failure 
 
Modifying Enzyme                                                  Outcome Ref 
Histone Acetyltransferase   
P300 Increased levels and activity in cardiac biopsies of patients with end stage 
heart failure (ischemic, dilated or idiopathic) 
 
(353) 
Deficiency of p300 in a knockout mouse model resulted in embryonic 
lethality with cardiac abnormalities 
(380) 
Histone Deacetylase   
HDAC1 and HDAC2 Increased levels in both infarcted and non-infarcted myocardium in the LAD 
ligation model of myocardial infarction (rat; wild type) 
 
(245) 
HDAC2 Deficiency of HDAC2 in a knockout mouse model was found to be cardio-
protective in response to both pressure overload and β-adrenergic 
stimulation  
 
(330) 
HDAC5 Deficiency of HDAC5 in a knockout mouse model developed non-fatal age 
related cardiac hypertrophy and an exaggerated hypertrophic response to 
both pressure overload and overexpression of calcineurin. 
 
(53) 
HDAC6 Deficiency of HDAC6 in a knockout mouse model developed a similar 
aberrant cardiac remodeling in response to AngII infusion but maintained 
systolic function compared to wild type.   
 
(80) 
HDAC9 Deficiency of HDAC9 in a knockout mouse model developed non-fatal age 
related cardiac hypertrophy and an exaggerated hypertrophic response to 
both pressure overload and overexpression of calcineurin. 
 
(386) 
HDAC5/9 Germline deletion of HDAC5 and HDAC9 resulted in severe embryonic 
cardiac abnormalities with ventricular septal defects and thin ventricular 
walls 
(53) 
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Table 4: Role of Sirtuins in Clinical and Preclinical Models of Heart Failure 
Sirtuin                                                  Outcome/Findings Ref 
SIRT1 Elevated levels in mice subjected to pressure overload, aging and induction of oxidative 
stress resulting in cardiac hypertrophy and fibrosis 
 
(7) 
Varying cardiac-specific overexpression resulted in different cardiac phenotypes when mice 
were subjected to oxidative stress induction and aging.  Mild to moderate expression 
attenuates remodeling and cardiac function whereas high expression promotes 
cardiomyopathy.   
 
(7) 
SIRT3 Deficiency in a knockout mouse model resulted in hypertrophy, fibrosis and cardiac 
dysfunction in response to aging, AngII and β-adrenergic stimulation. 
 
(123, 
313) 
 Transgenic expression in mice demonstrated cardio-protective effects in response to aging, 
AngII and β-adrenergic stimulation. 
 
(313) 
SIRT6 Decreased levels found in cardiac biopsies in patients with septal defects, Ischemic, dilated 
and idiopathic cardiomyopathy. 
 
(316) 
 Deficiency in a knockout mouse model results in development of cardiac hypertrophy and 
fibrosis at 8-12 weeks of age. 
 
(316) 
SIRT7 Deficiency in knockout mouse model results in significant cardiac hypertrophy and fibrosis 
with aging 
(331) 
      
 
  
  60 
Table 5: Histone Methylation in Heart Failure 
Cohort/Model Assessed             Methylation Changes                      Outcome Ref 
Patient biopsies with Dilated 
Cardiomyopathy &  
Dahl Sensitive Rats 
 
Differential H3K4me3 and H3K9me3 
profiles  
 
Methylation changes were enriched 
in genes related to cardiac function 
(159) 
Cardiac-specific PTIP knockout 
mouse model subject to 
isoproterenol and caffeine 
stimulation 
 
Reduction in H3K4me3 
 
 
No impact on hypertrophy or 
fibrosis but induced ventricular 
arrhythmias 
(309) 
Cardiac-specific PTIP knockout 
mouse model subject to 
pressure overload 
 
Reduction in H3K4me3 
 
 
Promotes maladaptive remodeling 
and dysfunction. 
(308) 
Patient biopsies with ischemic 
cardiomyopathy or dilated 
cardiomyopathy  
 
Increased expression of JMJD1A, 
JMJD2A, and JMJD2B mirrored with 
decreased H3K9 methylation 
 
Reactivation of Nppa and Nppb and 
silencing of ATP2A2 and Myh6 
(137) 
Patient biopsies with 
hypertrophic cardiomyopathy 
 
Increased levels of JMJD2A 
 
Increased expression of Nppb (388) 
Patient biopsies cardiac 
hypertrophy 
 
 
Increased expression of G9a 
methyltransferase and H3K9me2 in  
Myh6 promoter 
 
Reduced expression of Myh6 (125) 
Mouse model of pressure 
overload 
 
Decreased levels of H3K4me2  
Increased H3K27me3 & H3K36me2 
marks and KDM2A levels at the 
ATP2A2 promoter 
 
Increased expression of Myh7 and 
reduced expression of Atp2a2 
 
(9) 
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Decreased levels of H3K9me2 and 
H3K27me3 marks and  
Increased levels of H3K4me2 marks at 
the Mhy7promoter 
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Table 6: Role of DNA Methylation in Cardiomyocytes 
Enzyme                                Associated changes Ref 
DNMT1 Expression is elevated in response to metabolic stress including high glucose, 
homocysteine and the pollutant, phenanthrene.  Associated with reduced miR-
133a mediated regulation. 
 
(57) 
Repression of DNMT1 promotes a reduction in global cytosine methylation 
 
(90) 
DNMT3A Suppression results in altered sarcomere structure decreased beat rate 
variability, impaired calcium signaling and contractility.   
 
(90) 
DNMT3B Deletion resulted in abnormal sarcomeric structure, chamber dilation and 
reduced contractility under sham conditions but in pressure overload and β-
adrenergic stimulation, the hypertrophic response was blunted. 
 
Pressure overload induced alternative splicing of Myh7 gene due to differential 
methylation of three CpGs within intron 27  
 
(337) 
DNMT3A/DNMT3B Knock out of both isoforms in cardiomyocyte did not impair cardiac 
hypertrophy. 
 
Differential gene regulation of Aldh1l1, Krt8 and Sclc9a3 resulting from 
promoter hypomethylation with enhanced expression in pressure overload. 
 
(243) 
TET2 Promotes expression of Myh7 by hydroxymethylation at intergenic enhancer 
regions 
(116) 
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Table 7: Role of Histone Acetylation and Deacetylation in Cardiomyocytes 
 
Enzyme Injurious 
Stimuli 
Expression/Activity Phenotype Genetic Changes Ref 
P300  
Phenylephrine 
 
Increased activity 
 
Promotes 
hypertrophy 
 
 
Promotes GATA4 binding 
 
(5, 
120) 
Pressure 
overload 
Transgenic 
overexpression 
Promotes 
exaggerated 
hypertrophy 
 
De novo acetylation of Mef2 (353) 
HDAC1 Isoproterenol  
& 
 Pressure 
overload 
Deficiency of 
enzyme         
(conditional KO) 
No impact on 
hypertrophy 
 
 
 
 
No apparent alterations (222) 
HDAC2 No injury Transgenic 
overexpression 
Promotes 
hypertrophy 
 
 
Decreasing expression of Inpp5f 
activity of Akt, Pdk1 and 
Gsk3beta.   
(330) 
Phenylephrine Increased 
expression 
Promotes 
hypertrophy 
 
 
Reduced expression and binding 
of KLF4 to the Nppa promoter 
(163) 
Isoproterenol Deficiency of 
enzyme       
(conditional KO) 
No impact on 
hypertrophy 
 
 
No apparent alterations (222) 
HDAC1/2 Postnatal 
lethality 
Deficiency of both 
enzymes            
(conditional KO) 
Cardiac defects: 
dilated 
cardiomyopathy 
and arrhythmias 
 
 
Altered expression of genes 
involved in myofibrillar proteins 
(Tnni1 and Tnni2) and specific 
calcium channel subunits 
(CACNA1H and CACNA2D2). 
(222) 
HDAC3 No injury Deficiency of 
enzyme (conditional 
KO) 
Hypertrophy with 
alterations in 
myofibril and 
Aberrant expression of genes 
involved in cardiac metabolism 
(UPC2, UPC3, FACS, GLUT4) 
(223) 
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mitochondrial 
structure 
 
 Isoproterenol Transgenic 
overexpression 
Increased 
proliferation at 
birth but showed 
similar 
hypertrophic 
response as WT 
 
 
Reduction of cyclins, CDKs, and 
E2F transcription factors and up-
regulation of the negative 
regulators of cell cycle (Cdkn1a, 
Cdkn1b, Cdkn1c, and Cdkn2c) 
(329) 
SIRT1 No injury Transgenic over-
expression 
Promotes 
hypertrophy 
 
Deacetylation and increased 
activity of Akt1  
(314) 
SIRT3 Phenylephrine 
& 
Angiotensin-II 
Increased 
expression 
Promotes myocyte 
survival 
 
 
Deacetylation of Ku70 
preventing Bax-mediated 
apoptosis 
(315) 
SIRT6 No injury Deficiency of 
enzyme                 
(conditional KO) 
Promotes 
hypertrophy 
Enhanced H3K9 acetylation and 
promoted binding and 
transcriptional activity of c-Jun 
(316) 
Isoproterenol 
& 
Pressure 
overload 
transgenic over-
expression 
Prevented 
hypertrophic 
response 
SIRT6 deacetylates H3K9 and 
prevents activation of IGF-
signaling related genes 
(316) 
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Table 8: Changes in Histone Methylation in Cardiomyocytes 
Histone Modifying Enzyme Methylation changes            Role in myocyte  Ref 
 
Histone Methyltransferase 
 
DOT1L Promotes H3K79me2 
marks 
 
Involved in cardiomyocyte differentiation and 
maturation 
(252) 
G9a Promotes H3K9me2 
methylation 
 
Transcriptional silencing of Myh6 in pressure 
overload by recruiting DNMTA 
(125) 
EZH2 Promotes H3K27 
methylation 
 
 
Prevents expression of hypertrophic genes and 
can be inhibited by interaction with the lncRNA 
Chaer 
(349) 
KMT2B/KMT2C Promotes H3K4me3 
methylation 
 
 
 
Important in cardiomyocyte response to injury.  
Regulates expression of ADRA1A, ADRA1B, JUN, 
ATP2A2, ATP1A2, SCN4B, and CACNA1G in 
pressure overload. 
(309, 
310) 
Histone Demethylase  
JMJD1A Demethylates H3K9me1 
and H3K9me2 
 
 
Upregulated in order to compensate for 
knockdown of JMJD2A 
(137) 
JMJD2A Demethylates H3K9me2 
and H3K9me3 
 
 
 
Involved in promoting cardiac hypertrophy by 
binding to FHL1 promoter and recruiting 
myocardin and serum-response factor 
(388) 
JMJD1A/2A Demethylation of H3K9 
methylation 
 
Prevents expression of hypertrophic genes (137) 
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Table 9: DNA Methylation in Fibroblasts 
Modifying 
Enzyme 
Response to activation Effect on fibrosis    Associated changes Ref 
DNMT1 Increased levels in 
hypoxia 
Induction of profibrotic 
markers SMA and Col1. 
 
Global hypermethylation (27
3, 
350
) 
DNMT3A Increased levels in 
hypoxia 
EndMT of human coronary 
endothelial cells. 
 
Promoter methylation of 
RASAL1. 
(36
6, 
367
) 
 Increased levels after 
PDGF treatment 
Increased proliferation and 
levels of SMA and Col1. 
 
Regulates expression of 
RASSF1A. 
(32
5) 
DNMT3B Increased levels in 
hypoxia 
Induction of profibrotic 
markers SMA and Col1. 
 
Global hypermethylation. 
 
(35
0) 
TET3 Suppressed in 
response to TGFβ 
Induction of pro-fibrotic 
markers. 
 
Promoter methylation of RASAL1 
due to impaired TET3- 
demethylation. 
(32
1) 
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Table 10: Acetylation and Deacetylation in Fibroblasts 
Modifying Enzyme                                                  Association with fibrosis Ref 
p300 Elevated levels are associated with enhanced collagen expression elicited by 
Smad-dependent TGFβ activation.     
  
(33) 
HDAC1 and 2 
 
Increased levels in ischemic myocardium.    
Treatment with Class I HDAC inhibitor (Mocetinostat) reduced expression of 
αSMA, Col III, and MMP2.    
 
(245) 
HDAC4 Knockdown resulted in inhibition of TGFβ-induced αSMA expression, associated 
with regulation of Akt phosphorylation. 
     
(110, 
119) 
 Regulates expression of MMP9 and MMP13.  
  
(266) 
HDAC6 siRNA knockdown impaired TGFβ-induced αSMA expression.  
   
(110) 
HDAC8 siRNA knockdown impaired TGFβ-induced αSMA expression.    (110) 
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Table 11: Histone Methylation and Demethylation in Fibroblasts 
Modifying Enzyme                   Role in fibroblasts Ref 
Histone Methyltransferase    
  
 
G9a Induction of expression in response to TGF-Smad3 promoting a 
fibrotic phenotype. 
 
(145) 
 Associated with increased H3K9me1 levels. 
 
(145, 
201) 
EZH2 Involved in COX2 repression by H3K9me3. 
 
(69) 
 Promotes PPARy silencing by H3K27me3 on 3' exons.  
    
 
(205) 
ASH1 Promotes expression of αSMA, TIMP-1, collagen-1 and TGFβ 
through addition of H3K4me3 marks. 
 
(254) 
Histone Demethylase   
KDM2B Regulator of fibroblast function. (151) 
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Table 12: DNA Methylation in Immune Cells 
Cell type                                 Impact/Outcome Ref 
Haematopoetic stem cell Reduced DNMT1 activity prevents generation of lymphoid progenitor cells. (39) 
 Loss of DNMT3A and DNMT3B prevents cellular self-renewal and impairs 
differentiation. 
 
(52) 
 Tet2 is a negative regulator of HSC differentiation as loss promotes 
differentiation to the monocyte/macrophage lineage. 
 
(172) 
Neutrophils Hypomethylation of transcription factors (PU.1 and GFI1) and granular 
proteins (myeloperoxidase, elastase, and proteinase 3) associated with 
neutrophil differentiation. 
(276) 
   
Macrophage Macrophages isolated from hind limb ischemia and metabolic dysfunction 
model have differential promoter methylation promoting a pro-inflammatory 
M1 phenotype. 
 
(15) 
 Persistent differential methylation changes in monocytes in Type1 diabetic 
patients.  Hypomethylation of TXNIP was validated in monocytes exposed to 
high concentrations of glucose. 
 
(59) 
 DNMT1 and DNMT3B expression is increased in adipose tissue macrophages 
from ob/ob mice and is associated with a pro-inflammatory phenotype 
associated with increased methylation of the PPARy promoter. 
 
(345, 
379, 
381) 
 Reduced promoter methylation at the LXR and PPARy is associated with 
athero-protective effects. 
 
(46) 
 Hypermethylation of SOCS1 results in prolonged secretion of LPS induced 
TNFα and IL-6 secretion. 
 
(60) 
Dendritic cell Altered expression of DNMT1, DNMT3A and TET2 during monocyte to 
dendritic cell differentiation.  This was mirrored by dynamic changes in 
methylation and expression of SRC, PLEKHG6 and ITGB2. 
  
(389) 
  CpGs in the promoter region of CD209 become hypomethylated during 
differentiation of monocytes to dendritic cells. 
 
(41) 
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 The IL-4-JAK3-STAT6 pathway is important in regulating TET2 demethylation 
for differentiation of monocytes to dendritic cells. 
 
(334) 
 DNA hypomethylation, increased 5hmC and altered gene expression occur in 
response to infection with Mycobacterium tuberculosis. 
  
(251) 
T cells DNMT1 is involved along with the other DNMTs to varying degrees to 
maintain the Cd4 locus in a silenced state in CD8+ T cells. 
 
(293) 
Th1 Th1 cell acquisition is associated with demethylation at the IFN-y gene locus. 
 
(289) 
Th2 DNMT3A is recruited to the IFN-γ promoter and rapidly methylates the IFN-y 
promoter during Th2 polarization. 
(155) 
Th17 Th17 cells have marked demethylation at CpG regions in IL17A, Zfp362, Ccr6, 
Acsbg1, Dpp4, Rora and Dclk1 genes. 
 
(375) 
Memory T cell Differential methylation between memory and naïve CD4+ cells facilitating 
inflammatory gene expression (including IL-17A, IL-13 and IFNy) upon 
stimulation in memory cells. 
 
(175) 
Treg  Methylation in a conserved CpG-rich region upstream of FoxP3 promoter can 
influence stability of its expression in Treg cells. 
 
(167) 
 Involved in silencing FoxP3 expression in NK cells. (399) 
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Table 13: Histone Acetylation and Deacetylation in Macrophages 
Modifying Enzyme                                      Role  Ref 
Acetyltransferase   
p300 Promotes expression of IFNA, TNF and IL-6 in response to viral infection. 
 
(92) 
Deacetylase   
HDAC3 Suppresses IL-4 target gene expression by binding to PU.1 enhancer 
regions. 
 
(234) 
 Deficiency facilitates acquisition of an M2 phenotype enhanced expression 
of Arg1, Clec7a, Ym1, and Retnla 
 
(234) 
 Overexpression is seen in macrophages in atherosclerotic plaques and 
promotes expression of IL-6. 
 
(136) 
 Promotes expression of IFNβ. 
 
(58) 
HDAC5 Overexpression promoted expression of MCP-1 and TNFα.   
 
(259) 
HDAC6 Promotes LPS-induced proinflammatory phenotype  
 
(371) 
HDAC7 Increased expression found in thioglycolate-elicited peritoneal 
macrophages.  HDAC7 isoform interacts with HIF-1α to promote 
proinflammatory gene expression. 
 
(296) 
HDAC9 Deficiency impaired LPS-induced gene expression , improved cholesterol 
efflux, skewed to the M2 phenotype with increased acetylation at the 
ABCA1, ABCG1, and PPAR-γ gene promoters 
(45) 
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Table 14: Histone Acetylation and Deaceylation in Treg Cells 
Modifying Enzyme                                Role  Ref 
Acetyltransferase    
p300 Promotes Treg survival and suppressive activity 
 
(197) 
Histone Deacetylase   
HDAC3 Inhibits NFkB activation and IL2 expression in Treg cells. 
 
(342) 
HDAC6 Involved in suppressing FoxP3 through deacetylation as Treg cells from 
HDAC6 deficient mice exhibit increased expression of IL-10 and FoxP3 
compared to wild type. 
 
(28, 
76) 
HDAC9 Impairs Treg function through regulation of HSP70 and inhibition of STAT5 
transcriptional activity. 
 
(29, 
77) 
HDAC6/Sirt1 Combined deficiency of these improved preservation and increased 
proliferation of FoxP3+ Tregs 
(29) 
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Figure Legends 
Figure 1: Schematic overview highlighting epigenetic changes associated with cardiac injury that 
lead to the acquisition of hyperactive cellular phenotypes in cardiomyocytes, fibroblasts and 
immune cells, and promote aberrant pathological remodeling in the heart. 
 
Figure 2: Regulation of gene transcription by DNA methylation and demethylation in the promoter 
region.  The addition of a methyl group (-CH3) to carbon 5 on the cytosine ring (C), is catalysed 
by the DNA methyltransferase (DNMT) enzymes forming 5-methylcytosine (5MeC).  S-
adenosylmethionine (SAM) is utilized as a methyl donor that is subsequently converted to S-
adenosylhomocysteine (SAH) upon donation.  Methyl-CpG-binding proteins (MeCP) and methyl-
CpG-binding domain protein (MBD) proteins are recruited to 5MeC resulting in gene silencing by 
preventing transcription factor (TF) and binding of RNA polymerase II (RNApolII) binding.  
Conversely, removal of methylated cytosines can be enzymatically carried out by the ten-eleven 
translocation (TET) enzymes, which oxidize 5MeC to 5-hydroxymethylcytosine (5hMeC).  Small 
molecule inhibitors of DNMT activity prevent 5MeC formation and together these processes 
promote gene expression by allowing TF and RNApolII to bind to the DNA. 
 
Figure 3: Control of gene expression through regulation of chromatin structure by acetylation and 
methylation of histone proteins.  Formation of heterochromatin structure and repression of gene 
expression is facilitated by both the removal of acetyl groups from histone tails by histone 
deacetylases (HDACs) and the actions of histone lysine methyltransferases (HMTs) and 
demethylases (HDMs) forming repressive histone marks (H3K9, H3K20, H3K27).  Conversely, 
promotion of gene expression and euchromatin structure is carried out by enzymatic addition of 
acetyl groups by histone acetyltransferases (HATs) and the actions of HMTs and HDMs forming 
active histone marks (H3K4, H3K26, H3K79).Abbreviations: HMTs: Histone Methyltransferases 
HDMs: Histone Demethylases, HATs: Histone Acetyltransferases, HDACs: Histone Deacetylases, 
CH3: methyl group.  Yellow pentagon:  Active histone marks, Blue pentagon: Repressive histone 
marks, Green marks: active acetylation marks  
 
 
Didactic Figure Legends 
Figure1: Teaching Points: This illustrated figure demonstrates that various types of injury to the 
heart can drive epigenetic changes in cardiomyocytes, fibroblasts and immune cells. These 
epigenetic changes can result in the acquisition of aberrant phenotypes which drive pathological 
remodeling in the heart which ultimately leads to the development of heart failure. 
 
Figure 2: Teaching Points: This illustrated figure highlights the regulation of gene expression by 
DNA methylation (gene repression) and demethylation (gene activation) at the promoter region of 
a gene. 
 
Figure 3: Teaching Points: This illustrated figure facilitates understanding of gene regulation by 
modifications of the amino-terminal tails of histone proteins, focusing on specifically the 
modifications acetylation and methylation. It also highlights the active and repressive histone 
marks that are associated with active gene expression or gene silencing. 
Further Reading 
Cross-References 
Cardiac fibroblast physiology and pathology 
Cardiovascular responses to stress 
Cellular basis of physiological and pathological myocardial growth (legacy) 
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Intracellular signaling of cardiac fibroblasts 
Myocardial cell signaling during the transition to heart failure 
Fetal programming and cardiovascular pathology 
General cardiac response to injury 
Obesity and nutrition effects on cardiac structure and function 
Pathophysiology of heart failure 
Wound healing 
Epigenetics and environmental stressors 
Supplementary Information 
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